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Abstract 
Short-term abstinence effects in experienced electronic cigarette users 
 
Nicholas J. Felicione 
Nicotine/tobacco dependence is a problem that negatively affects health at an individual and 
population level. Nicotine/tobacco dependence may be best assessed by measuring withdrawal 
symptoms of a nicotine/tobacco user who abstains from use. Withdrawal symptoms experienced 
by cigarette smokers are well characterized, including deficits in attention and memory, as well 
as self-reported cravings, urges, and other symptoms. While withdrawal in cigarette smokers has 
been studied extensively, little is known about dependence and withdrawal associated with 
newer products, such as electronic cigarettes (ECIGs). ECIGs can deliver nicotine comparably to 
tobacco cigarettes, indicating that they may have the potential to cause dependence. However, 
extant work assessing ECIG dependence and withdrawal is confounded by current or previous 
cigarette smoking in ECIG users. Thus, the purpose of this project was to characterize cognitive, 
subjective, and physiological measures of ECIG withdrawal in ECIG users who are not regular 
cigarette smokers. Eleven ECIG users that were primarily nonsmokers participated in two, 3.5-
hour sessions that differed by ECIG use: 180 minutes ad lib ECIG use and 180 minutes 
abstinent. Outcome measures included subjective questionnaires of withdrawal and nicotine 
effects, heart rate, cognitive assessments of sustained attention, working memory, and inhibitory 
control, and ECIG reward. Participants subjectively reported more craving, urges, and desire to 
vape at 120 to 180 minutes of abstinence compared to baseline. Participants also had poorer 
accuracy on an inhibitory control task at 120 minutes of abstinence compared to baseline 
abstinence or 120 minutes of ad lib ECIG use. Additional analyses included assessing 
characteristics that predict ECIG dependence, characterizing ad lib puff topography, and 
predicting withdrawal based on puff topography. Higher nicotine concentrations, daily ECIG 
use, longer durations of ECIG use, and higher wattages were associated with increased nicotine 
dependence. Results of this study demonstrate preliminary evidence of short-term withdrawal in 
ECIG users that are primarily nonsmokers, though findings are limited by a small sample size. 
Future research should be continue with similar experimental designs but increase sample size 
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Chapter 1 - Introduction 
Electronic Cigarettes  
Since becoming commercially available around 2007, the popularity of electronic 
cigarettes (ECIGs) has increased dramatically. By 2010, ECIGs were more commonly searched 
on the internet than tobacco products such as snus or nicotine replacement therapies (Ayers, 
Ribisl, & Brownstein, 2011). From 2010 to 2013, ever use of ECIGs among adults increased 
from below 2% to approximately 13% (McMillen, Gottlieb, Shaefer, Winickoff, & Klein, 2015). 
This increase in prevalence is consistent across most demographic groups, including both sexes, 
most age groups, and former and current smokers (King, Patel, Nguyen, & Dube, 2015). Recent 
national data also show that approximately 13% of adults have ever used ECIGs, as well as that 
3.7% - 4.5% currently use ECIGs (Mirbolouk et al., 2018; Schoenborn & Gindi, 2015; Wilson & 
Wang, 2017). ECIGs are now the second most commonly used nicotine product (cigarettes being 
the most common), surpassing alternative tobacco products such as cigars and smokeless tobacco 
(Phillips et al., 2017). Additionally, ECIGs are more commonly used in younger generations, 
with over 20% of adults aged 18-24 having ever tried an ECIG and use consistently declining 
with increasing age (Schoenborn & Gindi, 2015). Rates of lifetime ECIG use are higher in 
current (~47%) and former (~55%) cigarette smokers than never cigarette smokers (3.2%) 
(Schoenborn & Gindi, 2015). Similarly, rates of current use of ECIGs (i.e., every day or some 
days) are close to 16% for current cigarette smokers, 22% for former cigarette smokers, and 
0.4% for never cigarette smokers (Schoenborn & Gindi, 2015). Also notable is that lifetime and 
current ECIG use is more likely among cigarette smokers who have made a quit attempt in the 
past year, relative to cigarette smokers who did not make an attempt (Schoenborn & Gindi, 
2015). 
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ECIGs are a class of electronic nicotine delivery devices, or battery-operated products 
intended to delivery nicotine and other flavorants to a user (Brandon et al., 2015; Brown & 
Cheng, 2014). They all share some common features: battery, heating element, storage 
component, and liquid solution (Brown & Cheng, 2014). The liquid solution typically contains 
nicotine, solvents (propylene glycol and vegetable glycerin), and flavorants. In most cases, the 
battery will be activated by a flow sensor upon puffing or a manual press of a button. The battery 
provides power to the heating element such as a coil, which contains a wick to soak up the 
solution and an atomizer that aerosolizes the solution. Finally, the user inhales the aerosol 
through the mouthpiece. Still, ECIG designs and features have changed tremendously since their 
emergence, and there remains enormous variety in the currently available products. For example, 
1st generation devices (also known as “cig-alikes”) model the design of a cigarette with a 
mouthpiece that resembles a cigarette filter and an LED light that resembles the burning end of a 
cigarette rod (Brown & Cheng, 2014). These devices are pre-filled with nicotine solution and are 
disposable after use. More modern products no longer retain a cigarette-like resemblance. These 
2nd generation ECIGs (also known as “tank” models) typically hold the solution in a tank with or 
without an atomizer, and individuals can refill the solution as needed. Even more recently, a slew 
of 3rd generation ECIGs (also known as “mods”) have emerged, allowing individuals to build 
their own atomizers, as well as manipulate the battery voltage and atomizer resistance of the 
ECIG (Brandon et al., 2015; Farsalinos et al., 2014). Newer 4th generation (also known as “pods” 
or “pod mods”) have gained popularity, that typically contain high concentrations of nicotine 
salts (Eissenberg et al., 2018). These designs also allow the user more freedom to choose the 
nicotine content, solvents, and flavorants of their solution. Such ECIG models allow the user 
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great control over product features, which results in a greater user influence on the nicotine yield 
of the device.  
Indeed, the level of nicotine delivered to the user is influenced by both features of the 
ECIG design and behaviors of the user. As for design features, some ECIGs deliver little to no 
nicotine to the user while other ECIGs deliver levels of nicotine that surpass that for a cigarette 
(Shihadeh & Eissenberg, 2015). Those better able to deliver nicotine tend to have increased 
battery power (Kosmider, Sobczak, Knysak, & Goniewicz, 2014; Talih et al., 2015; Wagener et 
al., 2017), and thus later generation models are more efficient delivery devices than the 1st 
generation (Bullen et al., 2010; Vansickel, Cobb, Weaver, & Eissenberg, 2010). It is not 
surprising, therefore, that many ECIG users report switching from the cig-alike to more 
advanced models (Yingst et al., 2015). Of course, increasing the nicotine concentration of the 
liquid solution also results in increased nicotine delivery to the user (Hiler et al., 2017; Ramôa et 
al., 2016; Talih et al., 2015), as may changing the ratio of the solvents propylene glycol and 
vegetable glycerin (Kosmider et al., 2014). Yet even when the device features and liquid 
ingredients are held constant, the levels of nicotine delivered may differ substantially between 
ECIG users. Such differences are likely due to users’ puffing behavior, including their number, 
duration, and volume of puffs. Experienced ECIG users have shown to take puffs that are 
approximately twice as long as ECIG-naïve cigarette smokers (Farsalinos, Romagna, Tsiapras, 
Kyrzopoulous, & Voudris, 2013a), and longer puff durations are demonstrated to result in 
increased nicotine delivery (Hiler et al., 2017; Talih et al., 2015). Thus, the combination of the 
optimal device and users’ response to that device likely results in ECIGs that have the nicotine-
delivery capacity to produce cigarette-like, or potentially greater, levels of nicotine dependence 
(Ramôa et al., 2016; Shihadeh & Eissenberg, 2015). Given that nicotine is a dependence-
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producing drug (Benowitz, 2010), the ability of ECIGs to effectively deliver nicotine has 
important implications for individual and public health. Thus, it is essential to begin 
understanding nicotine dependence in the context of ECIG use, focusing on individuals that are 
ECIG users.  
Nicotine Dependence 
Nicotine/tobacco dependence is a recognized medical condition in the Diagnostic and 
Statistical Manual of the American Psychiatric Association (APA; APA, 2013) as well as the 
International Classification of Diseases (World Health Organization, 1992). According to the 
APA (2013), tobacco use disorder is defined as “A problematic pattern of tobacco use leading to 
clinically significant impairment or distress,” (p. 571) including criteria such as tolerance and 
withdrawal (see Table 1 for full criteria; APA, 2013). Tolerance is defined as a need for 
increased amounts of tobacco to achieve the same effect, or a reduced effect with continued use 
of the same amount of tobacco. For example, non-cigarette smokers exposed to nicotine 
experience aversive effects including dizziness and nausea at lower nicotine doses than cigarette 
smokers, suggesting that cigarette smokers may have become tolerant to, or need increased 
amounts of nicotine to experience, these adverse effects (Pomerleau, 1995). A similar trend is 
seen for positive effects (e.g., head rush, arousal, vigor), even when controlling for differences in 
plasma nicotine concentration between smokers and non-smokers (Perkins, Epstein, Grobe, & 
Fonte, 1994). Similarly, non-cigarette smokers show greater increases in heart rate and systolic 
blood pressure in response to nicotine than cigarette smokers (Pomerleau, 1995). Along with 
subjective and physiological tolerance, there is evidence of pharmacokinetic tolerance, with non-
cigarette smokers revealing higher plasma nicotine concentrations than cigarette smokers after 
acute nicotine administration (Srivastava, Russell, Feyerabend, Masterson, & Rhodes, 1991). 
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Still, while tolerance to nicotine is a criterion for tobacco dependence, it is considered a 
relatively weak indicator of dependence (Perkins, 2002). This weak relationship is evidenced by 
the lack of differential tolerance between dependent and non-dependent smokers, and the lack of 
association between tolerance and cessation success (Perkins et al., 2001; Perkins et al., 2002). 
For example, it might be expected that those smokers more tolerant to nicotine would be the least 
likely to quit smoking successfully, because they would be those more dependent on nicotine. 
However, research does not support this idea, rather demonstrating that tolerance may be 
unrelated to post-cessation withdrawal and relapse (Perkins et al, 2002). 
Withdrawal, in contrast, is a particularly important marker of dependence. The criterion 
of withdrawal is defined as experiencing a characteristic tobacco withdrawal syndrome or using 
tobacco/nicotine to relieve or avoid that withdrawal syndrome (APA, 2013). Table 2 
demonstrates the APA (2013) diagnostic criteria for tobacco withdrawal. As shown in this table, 
cigarette smokers often report the following symptoms of withdrawal experienced during a 
period of abstinence: cravings, difficulty concentrating, drowsiness, irritability, moodiness, and 
depression (Etter, 2005; Hughes & Hatsukami, 1986; Welsch et al., 1999). These aversive effects 
may drive smokers to use cigarettes or other nicotine/tobacco products to relieve or avoid 
withdrawal symptoms. For example, nicotine replacement products (e.g., nicotine patch, nicotine 
gum) are used to deliver nicotine to the user to mitigate aversive effects during a cessation 
attempt, and the dose of nicotine delivered can be slowly decreased over time as the cigarette 
smoker transitions to complete abstinence (Stead et al., 2012). In one study, the use of a nicotine 
patch resulted in increased positive symptoms (e.g., positive affect) and decreased negative 
symptoms (e.g., negative affect, craving, difficulty concentrating) which were related to a 
significantly lower risk of relapse following cessation among smokers (Ferguson, Shiffman, & 
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Gwaltney, 2006). Additionally, smokers who report withdrawal effects such as anger, depressed 
mood, and craving are observed to have a shorter time to relapse following cessation (Swan, 
Ward, & Jack, 1996). These and other data (Baker, Breslau, Covey, & Shiffman, 2012; Ferguson 
et al., 2006; Swan et al., 1996) support the idea that the severity of tobacco withdrawal is a 
significant predictor of nicotine/tobacco dependence. Consequently, it is important to consider 
the phenomenon of withdrawal as an indicator of ECIG dependence.  
Nicotine Withdrawal 
 Nicotine/tobacco withdrawal symptoms can be characterized using a variety of measures, 
which capture the subjective (Etter, 2005; Hughes & Hatsukami, 1986), physiological 
(Hendricks, Ditre, Drobes, & Brandon, 2006), and cognitive/behavioral (Ashare, Falcone, & 
Lerman, 2014; Heishman, Taylor, & Henningfield, 1994; Hughes, 2007b, McClernon, Addicott, 
& Sweitzer, 2015) experiences of smokers. Given the wide variation in the symptoms 
experienced by product users, studies that include all of these measures of are the most complete 
way to characterize withdrawal, and ultimately, understand dependence (Hughes, 2007b). Some 
of the most common methods for measuring nicotine/tobacco withdrawal are described below. 
Subjective reports of withdrawal. One of the most common methods for measuring 
withdrawal symptoms are subjective measures, or self-reports (for, review, see Hughes, 2007b), 
such as the Minnesota Nicotine Withdrawal Scale (MNWS; Hughes & Hatsukami, 1986), the 
Cigarette Withdrawal Scale (Etter, 2005), and the Shiffman-Jarvik Withdrawal Scale (Shiffman 
& Jarvik, 1976). While these measures differ in measurement scale type (e.g., visual analog, 
Likert) and brevity, all are designed to assess validated tobacco withdrawal symptoms and show 
substantial overlap with the DSM-V and ICD-10 criteria for nicotine withdrawal (Hughes, 
2007b). Most of these measures appear to have adequate internal reliability, test-retest reliability, 
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and content validity, and they all consider those commonly reported symptoms mentioned above 
(Hughes, 2007b; Hughes & Hatsukami, 1986; Shiffman & Jarvik, 1976). For example, use of 
these measures demonstrates that dependent cigarette smokers experience increases in symptoms 
such as difficulty concentrating, craving, irritability, and impatience with increasing periods of 
abstinence (Hughes & Hatsukami, 1986; West, Ussher, Evans, & Rashid, 2006; Welsch et al., 
1999). Moreover, smokers’ ratings of these symptoms decrease significantly following 
resumption of cigarette smoking (Etter & Hughes, 2006; Blank, Disharoon, & Eissenberg, 2009) 
or use of another nicotine/tobacco product (Molander, Lunell, & Fagerström, 2000; Muramoto, 
Ranger-Moore, & Leischow, 2003; Thornley et al., 2010). 
While many of these withdrawal symptoms peak days after abstinence (Hughes, 2007a), 
they can be experienced within much shorter periods. For instance, ratings of withdrawal 
symptoms are reliably increased following a period of overnight abstinence (> 8 hours), from not 
only cigarettes (Blank et al. 2009; Breland, Buchhalter, Evans, & Eissenberg, 2002; Buchhalter 
& Eissenberg, 2000), but also tobacco waterpipes (Maziak et al., 2009) and smokeless tobacco 
(Gray, Breland, Weaver, & Eissenberg, 2008). Some evidence suggests that withdrawal 
symptoms may manifest even earlier, at least for cigarette smokers, with significant increases 
emerging between 30 and 180 minutes of abstinence (Hendricks et al., 2006).  
Cognitive measures of withdrawal. Measures of performance on cognitive tasks are 
common objective measures of nicotine withdrawal (Ashare et al., 2014; Heishman et al., 1994; 
Hughes, 2007b, McClernon et al., 2015). Research on withdrawal-induced cognitive deficits 
tends to focus on three key cognitive domains of executive function (mental processes needed for 
attention and control of behavior; Diamond, 2013): sustained attention, working memory, and 
inhibitory control (Ashare et al., 2014; McClernon et al., 2015). 
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Sustained attention. Sustained attention refers to the ability to maintain alertness to 
detect unpredictable signals over an extended length of time (McClernon et al., 2015). It is an 
executive function that allows individuals to discriminate between targets and distractors (Ashare 
et al., 2014; Sarter, Givens, & Bruno, 2001), and appears to involve activation of the prefrontal 
and parietal regions of the right hemisphere (Kozink, Lutz, Rose, Froeliger, & McClernon, 2010; 
Sarter et al., 2001). Examples of daily activities that involve sustained attention are reading, 
playing video games, and driving a vehicle. The inability to sustain attention while engaging in 
such activities may be reported as “difficulty concentrating” by smokers during a period of 
abstinence (Ashare et al., 2014; McClernon et al., 2015).  
 A number of studies have assessed the effect of nicotine/tobacco withdrawal on sustained 
attention using a variety of tasks, including the Rapid Visual Information Processing task (RVIP, 
Wesnes & Warburton, 1984; McClernon et al., 2008; Hendricks et al., 2006), continuous 
performance tasks (McClernon et al., 2008; Harrison, Coppola, & McKee, 2009), and vigilance 
tasks (Parrot, Garnham, Wesnes, & Pincock, 1996; Hatsukami, Fletcher, Morgan, Keenan, & 
Amble, 1989; Wesnes, Simpson, & Kidd, 1988). All generally require participants to maintain 
vigilance to respond to targets appropriately over relatively long durations (McClernon et al., 
2015). These tasks are relatively simple, in efforts to measure sustained attention per se, rather 
than aspects of other executive functions. For example, the RVIP task involves a series of single 
digits being presented on a screen at a rapid pace for an extended length of time, requiring 
participants to indicate when they notice three consecutive odd digits or three consecutive even 
digits (Wesnes & Warburton, 1984).  
 Deficits in sustained attention have been demonstrated reliably for daily cigarette 
smokers that have abstained from nicotine/tobacco use. For example, McClernon et al. (2008) 
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assessed the effects of overnight nicotine/tobacco withdrawal (9-11 hours) on multiple measures 
of sustained attention (e.g., RVIP, continuous performance task) in a sample of daily cigarette 
smokers. Smoking abstinence was associated with poorer accuracy on both tasks, though the 
continuous performance task revealed differences in speed (i.e., greater variability in response 
time for abstinent versus satiated conditions) that were not observed on the RVIP. This same 
pattern has been demonstrated consistently for abstinent and satiated cigarette smokers for the 
RVIP at different durations of abstinence (17 hours, Atzori, Lemmonds, Kotler, Durcan, & 
Boyle, 2008; 10 hours, Mancuso, Andres, Ansseau, & Tirelli, 1999; 12 hours, Leventhal, Waters, 
Moolchan, Heishman, & Pickworth, 2010; Parrott & Craig, 1992; “overnight”, Wesnes & 
Warburton, 1984). Additionally, slowed reaction time for abstinent smokers on the RVIP may 
emerge between 30 to 240 minutes of abstinence (Hendricks et al., 2006). Convergent results 
have been observed using other measures of sustained attention (e.g., vigilance task, continuous 
performance task; Hatsukami et al., 1989; Parrott et al., 1996; Myers, Taylor, Moolchan, & 
Heishman, 2008). Of course, some studies have shown a lack of effect of nicotine/tobacco 
withdrawal on measures of sustained attention (Cook, Gerkovich, Graham, Hoffman, & 
Peterson, 2003; Kleykamp, Jennings, & Eissenberg, 2011), but it is possible that cross-study 
differences in task, sample, and method of nicotine administration may account for different 
findings. Importantly, abstinence-induced decrements in sustained attention have been found 
repeatedly in the literature, even with these cross-study differences in task, method of nicotine 
administration, and duration of abstinence (see Evans & Drobes, 2009 for review; Atzori et al. 
2008; Foulds et al., 1996; Mancuso et al., 1999; Myers et al., 2008; Wesnes & Warburton, 1984). 
Due to the overwhelming evidence demonstrating withdrawal-induced deficits in sustained 
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attention, it is considered a key measure of cognition in nicotine withdrawal studies (Ashare et 
al., 2014; McClernon et al., 2015). 
 Working memory. Working memory refers to the concurrent storage and manipulation of 
information for a short period of time, with the prime function being coordination of resources 
(Baddeley, 1992; Baddeley & Hitch, 1994). Working memory is essential for making sense of 
events that unfolds over time, such as solving math in your head or relating the beginning and 
end of a paragraph (Diamond, 2013). Additionally, working memory has an important role in 
reasoning and the performance of goal-directed behavior (Diamond, 2013; McClernon et al., 
2015). The working memory system can be deconstructed into three subparts: central executive, 
phonological loop (verbal), and visuospatial sketchpad (nonverbal). The central executive 
includes an attentional controller and coordinates information from the other working memory 
components (Baddeley, 1992). The phonological loop can be further broken down into a 
phonological store (holds auditory information for up to two seconds) and an articulatory control 
process (maintains information and can register visual information into the phonological store). 
For example, the phonological store is important in speech perception and understanding, while 
the articulatory control process is involved in speech production and is used to rehearse and store 
verbal information. Together, these systems may be used to manipulate and rehearse verbal 
information, as in trying to remember a phone number. The visuospatial sketch pad performs 
similar functions, but is associated with visuospatial imagery as opposed to auditory information 
(Baddeley, 1992). It is useful for tasks such as spatial navigation and solving puzzles, and is 
important in the processing of shapes and colors of images. The prefrontal cortex is considered to 
be an essential brain area involved in working memory tasks (Knudsen, 2007), though 
association areas may differ depending on the aspect of working memory (e.g., verbal – language 
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areas in temporal and inferior parietal cortex, Schumacher et al., 1996; visuospatial – inferior 
parietal cortex and high-order visual areas in occipital cortex, Smith, Jonides, & Koeppe, 1996). 
Overall, working memory involves the attending to and processing of stimuli, and allows for 
rehearsal, retention, and manipulation of information.  
 One measure of working memory is the n-back task, which typically involves the 
presentation of a letter sequence and the requirement that participants indicate when the target 
stimulus does or does not match a stimulus presented “n” letters back. For example, in a 2-back 
condition, participants must respond “yes” if the letter presented is the same as the letter 
presented two letters back (e.g., A - B - A), or “no” if the letter presented is not the same as the 
letter presented two letters back (e.g., A- B- C). In one study, a parametric assessment of the n-
back task was used to compare working memory performance of abstinent (> 13 hours) and 
satiated smokers (Mendrek et al., 2006). For this assessment, the researchers used conditions of 
different cognitive loads, including a 0-, 1-, 2-, and 3-back condition. Generally, abstinent 
smokers made more errors (saying “yes” to a non-target, saying “no” to a target) than satiated 
smokers, and had slower reaction times for the 2-back condition. The findings from this study 
may demonstrate that greater working memory impairment is observed at higher working 
memory loads (e.g., 0-back vs 2-back; McClernon et al., 2015; Mendrek et al., 2006).  
 Many studies demonstrate converging results of poorer n-back performance when 
smokers are in withdrawal (6 – 24 hours abstinence) as compared to satiated (Ernst, Hieshman, 
Spurgeon, & London, 2001; Falcone et al., 2014; Grundey et al., 2015; Jacobsen et al., 2005; 
Kleykamp et al., 2011; Mendrek et al., 2006; Myers et al., 2008). Similar findings have also been 
observed with different measures of working memory (digit recall – Snyder, Davis, & 
Henningfield, 1989). Similar working memory decrements are observed for abstinent cigarette 
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smokers (> 12 hours) when compared to nicotine administered in vehicles other than cigarettes, 
for instance nasal spray (Myers et al., 2008) and transdermal nicotine (Kleykamp et al., 2011).  
Like sustained attention, there are several studies that have reported no differences in working 
memory between abstinent and satiated smokers (Jacobsen, Pugh, Constable, Westerveld, & 
Mencl, 2007; Wesnes, Edgar, Kezic, Salih, & De Boer, 2013). However, there is greater 
evidence supporting withdrawal-induced working memory deficits, and studies demonstrating 
null results report potential issues with psychometric properties of the task (Wesnes et al., 2013). 
 Inhibitory control. Inhibitory control is an aspect of executive function that involves 
controlling one’s attention, behavior, and thoughts to block out irrelevant stimuli while attending 
to appropriate information (Diamond, 2013). Inhibitory control also describes the ability to 
inhibit a dominant or automatic response (e.g., expecting to respond, but then needing to inhibit 
that response; McClernon et al., 2015). For example, a driver of a manual car may be unable to 
inhibit the automatic responses of shifting gears or using a clutch pedal when driving an 
automatic car. The main brain area associated with inhibitory control is the prefrontal cortex, 
specifically the right inferior frontal cortex (Kozink, Kollins, & McClernon, 2010). Inhibitory 
control allows individuals to control impulses and remain focused on a task or goal. 
Additionally, it allows individuals to selectively attend to important stimuli, rather than 
immediately responding to all irrelevant stimuli in the environment (Diamond, 2013). For 
example, selective attention is needed at a cocktail party, when it is important to inhibit 
processing of the voices of guests except for the single individual with whom you are holding a 
conversation.  
 Tasks that measure inhibitory control typically involve participants responding to certain 
stimuli, and withholding responses to other stimuli (McClernon et al., 2015): Go/No-Go Task 
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(Harrison et al., 2009; Kozink, Kollins et al., 2010; McClernon et al., 2008), Stop Signal Task 
(Ashare & Hawk, 2012), and Stroop task (Atzori et al., 2008; Grundey et al., 2015; Zack, 
Belsito, Scher, Eissenberg & Corrigall, 2001. For example, a Cued Go/No-Go task was used to 
assess smokers at differing levels of abstinence (Harrison et al., 2009). This task measures an 
individual’s ability to respond when appropriate and withhold a response when no response is 
required. Specifically, participants are presented with a cue that indicates whether the upcoming 
trial will require a response or no response. Next, they receive a target indicating whether a 
response is required or not, and this target may match or be incongruent with the prior cue. 
Poorer performance (e.g., longer reaction times) was observed for daily cigarette smokers 
following 5-hours and 17-hours of nicotine/tobacco deprivation compared to a non-deprived 
condition (Harrison et al., 2009). Similar performance decrements have been reported in 
cigarette smokers that had been overnight abstinent (Hatsukami et al., 1989; Kozink, Kollins et 
al., 2010; McClernon et al., 2008). Additionally, poorer performance on inhibitory control tasks 
has been observed for abstinent smokers (> 6 hours) using the Stop Signal task (Ashare & Hawk, 
2012) and the Stroop Task (Atzori et al., 2008; Grundey et al., 2015; Zack et al., 2001). Taken 
together, research consistently demonstrates that periods of nicotine/tobacco abstinence among 
cigarette smokers results in inhibitory control deficits.  
 Researchers have worked to use these same measurement tools to evaluate dependence 
and withdrawal related to ECIG use. Such work remains in its infancy for multiple reasons. First, 
ECIGs are a relatively newer tobacco product, having emerged into the U.S. market in 2007 
(Hemmerich, Klein, & Berman, 2017). Additionally, ECIG products have evolved at a rapid rate 
since their introduction (Brandon et al., 2015; Wagener et al., 2017). Over recent years, popular 
ECIGs have changed from cig-alikes to 2nd generation tank models, to 3rd generation mods that 
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have high battery power and many modifiable components, and more recently to 4th generation 
pods with high concentrations of nicotine salts. Thus, researchers are working to understand 
dependence and withdrawal associated with ECIG use while keeping up with advances in this 
relatively novel class of nicotine delivery products. 
ECIG Dependence and Withdrawal 
To date, there has been little research to evaluate nicotine dependence or withdrawal in 
exclusive ECIG users, though there has been one study to examine withdrawal in this sample 
over one week (Hughes et al., 2019b). Work that does exist confounds ECIG and cigarette use 
(Etter & Eissenberg, 2015; Hughes et al., 2019a), as the large majority of ECIG users are current 
or former smokers of cigarettes (Schoenborn & Gindi, 2015). For instance, a cross-sectional 
survey was administered to compare dependence on ECIGs relative to other tobacco products, 
though all of the ECIG users had a history of tobacco use: ECIG users who were current 
cigarette smokers, ECIG users who were former smokers, nicotine gum users who were former 
cigarette smokers, and current cigarette smokers who do not use ECIGs (Etter & Eissenberg, 
2015). Moreover, those ECIG users surveyed may have used ECIGs with or without nicotine. All 
respondents completed measures of nicotine/tobacco dependence in their original form (i.e., 
developed for cigarette dependence) or a form adapted for nicotine gum or ECIG products. 
Scores on these scales suggested that ECIGs are less dependence-producing than tobacco 
cigarettes and may be equally or less dependence-producing than nicotine gum (Etter & 
Eissenberg, 2015). This idea is also supported by other work that includes current ECIG users 
who formerly used cigarettes; dependence scores were shown to be lower, time to first product 
use in the morning was shown to be longer (i.e., the duration of product abstinence was longer), 
and ratings of nicotine/tobacco withdrawal and craving were shown to be lower for ECIGs 
ACUTE ABSTINENCE EFFECTS OF ECIG USERS 15 
relative to cigarettes (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & Voudris, 2013b; Foulds et 
al., 2015). Only one available study has suggested that ECIGs may produce higher levels of 
dependence than cigarettes (Johnson et al., 2018), though the large majority of the sample 
reported previous cigarette use (86.2%). The best evidence of dependence on ECIGs, and the 
phenomenon of ECIG withdrawal, requires evaluation of ECIG users with no history of cigarette 
or other tobacco use. 
Several product and ECIG use characteristics may be predictive of ECIG dependence. 
Use characteristics such as longer durations of ECIG use (Foulds et al., 2015; Johnson et al., 
2018), as well as daily ECIG use (Morean, Kirshnan-Sarin, & O’Malley, 2018), are associated 
with increased ECIG dependence. Additionally, frequency of ECIG use increased in an 
adolescent sample over 12 months along with increased dependence, which may be suggest that 
users are gaining tolerance (Vogel, Prochaska, Ramo, Andres, & Rubinstein, 2019). Liquid 
consumption is strongly correlated with the number of puffs taken and puff duration (Farsalinos 
et al., 2013a), and puff duration is associated with ECIG nicotine delivery (Blank et al., in press). 
However, others have found that vaping consumption variables may not be associated with ECIG 
dependence (Browne & Todd, 2018). Regarding product characteristics, using more advanced 
generations of ECIGs is associated with higher ECIG dependence (Foulds et al., 2015; Yingst et 
al., 2015). This finding may be a result of increased speed and concentration of nicotine delivery 
associated with newer generations of ECIGs (Wagener et al., 2017). Relatedly, higher nicotine 
concentrations (Hiler et al., 2017; Ramôa et al., 2016) and increased wattages (Kosmider, 
Spindle, Gawron, Sobczak, & Goniewicz, 2018; Talih et al., 2015) can increase nicotine yield 
and delivery, which may lead to increased ECIG dependence. Indeed, higher nicotine 
concentrations are associated with increased ECIG dependence (Foulds et al., 2015) and 
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increasing nicotine concentrations may be evidence of the development of tolerance (Vogel et al. 
2019). However, the interactive relationships between some of these variables (e.g., nicotine 
concentration, wattage, device type, liquid consumption) may complicate their associations with 
nicotine delivery and dependence (Shihadeh & Eissenberg, 2015). For example, studies that 
demonstrate the relationship between nicotine concentration and nicotine delivery hold other 
ECIG specifications constant (Hiler et al., 2017; Ramôa et al., 2016), but this is likely not 
ecologically valid. Indeed, individuals that use lower nicotine concentrations tend to vape at 
higher wattages and consume more liquid than individuals using higher nicotine concentrations 
(Smets, Baeyens, Chaumont, Adriaens, & Van Gucht, 2019). Though higher-powered devices 
may deliver nicotine more quickly, users of higher and lower powered devices have 
demonstrated similar plasma nicotine concentrations after a 2-hour ad lib vaping session 
(Wagener et al., 2017), indicating that users may vape differently to compensate for differences 
in ECIG specifications. Ultimately, more work must be done to understand how use 
characteristics and ECIG specifications interact to influence nicotine delivery and how these 
variables may promote dependence in ECIG users. 
Indeed, researchers have argued that nicotine dependence is product-specific, and should 
be assessed accordingly (Fagerström & Eissenberg, 2012). One reason for this argument is that 
products that deliver nicotine do so with different speeds of delivery to the brain (Henningfield 
& Keenan, 1993; West et al., 2000). Products that deliver nicotine more rapidly (e.g., cigarettes) 
are more likely to support dependence than those that deliver nicotine at a slower speed (e.g., 
nicotine patch; Le Houezec, 2003). As for ECIGs, Foulds et al., (2015) noted that these devices 
generally deliver nicotine more slowly and in lower concentrations compared to cigarette 
smoking. However, more recent generations of ECIGs have demonstrated an increased speed and 
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concentration of nicotine delivery (Wagener et al., 2017), which may lead to greater nicotine 
dependence in users of these devices compared to users of the original models. Evidence in 
support of this idea derives from the observation that dependence scores are higher among users 
of newer generations of ECIGs than users of “cig-alike” style ECIGs (Yingst et al., 2015). 
Another reason for this argument of product-specific dependence assessment is that nicotine may 
be a stronger reinforcer in the presence of certain non-nicotine stimuli (Perkins, Karelitz, & 
Boldry, 2017; Rupprecht et al., 2015). For example, nicotine may enhance the reinforcing 
efficacy of certain cues associated with nicotine/tobacco product use (Fagerström & Eissenberg, 
2012). While some cues may overlap between tobacco cigarettes and ECIGs (e.g., hand-to-
mouth movements, cloud of vapor/smoke, size/shape for some ECIG models), ECIGs are a 
different class of products that likely have distinct cues separate from traditional cigarettes (e.g., 
taste/aroma, size/shape for some ECIG models). As ECIGs continue to evolve, it is possible that 
cues shared with cigarettes will become less common and thus ECIG-exclusive cues will need to 
be considered for evaluation. This idea is evidenced by the change in ECIG design from cig-alike 
(e.g., LED light that resembles burning end of a cigarette, similar size/shape to cigarettes) to 
modern models (e.g., larger size, heavier weight, some require manual activation prior to each 
puff).  
Of course, the evaluation of ECIG dependence and withdrawal among users of a specific 
ECIG device/liquid combination is a challenge unlikely to be overcome in the current market. As 
of 2014, there were at least 460 different ECIG brands and at least 7,764 different liquid flavors 
available for purchase (Zhu et al., 2014). Additionally, the regulation of ECIGs will not be in full 
effect until 2022 (U.S. Food and Drug Administration, 2017), thus allowing manufacturers the 
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freedom to make design changes until that time. Still, work is needed on the evaluation of ECIG 
dependence and withdrawal in ECIG users without a history of cigarette use.  
Statement of the Problem 
 Nicotine/tobacco dependence is a problem that negatively affects health at an individual 
and population level. Currently, the tolerance and withdrawal experienced by cigarette smokers 
is well-established. Specifically, deficits in concentration, attention, and memory are commonly 
reported withdrawal symptoms that are objectively observed using cognitive tasks. Subjective 
measures indicate many symptoms that abstinent smokers report, such as cravings, urges, 
difficulty concentrating, anxiousness, among others. While withdrawal in cigarette smokers is 
well-categorized, less is known about dependence and withdrawal associated with newer 
products, such as ECIGs. Cigarette-like nicotine delivery has been reported for some ECIGs, 
indicating that they also may be dependence causing. However, extent work that addresses the 
ECIG dependence and withdrawal confounds ECIG and cigarette use. Thus, the purpose of this 
project is to characterize the cognitive, subjective, and physiological measures of ECIG 
withdrawal during a period of abstinence in ECIG users with little history of cigarette smoking.  
Clinical and Regulatory Implications 
 Characterizing ECIG dependence and withdrawal is meaningful for clinicians and 
tobacco regulators. Clinicians should evaluate ECIG use and dependence with similar methods 
as used for cigarettes. Additionally, development of treatment efforts for ECIG cessation may be 
necessary. To date, no studies have been published that assess the best methods to help ECIG 
users quit. Knowledge of the timecourse and primary symptoms of withdrawal will aid clinicians 
and regulators in determining the optimal treatments for ECIG cessation. Additional concerns 
arise when considering cigarette smokers switching to ECIG use, which may not result in a 
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significant reduction of nicotine dependence. A similar issue is dual use of cigarettes and ECIGs, 
because these users are likely to strengthen their dependence on nicotine if ECIGs are 
dependence-causing. The long-term health effects of ECIG use remain unknown, and efforts 
should be targeted towards complete nicotine cessation or use of FDA-approved nicotine 
replacement therapies for all users.  
 Additionally, the Family Smoking Prevention and Tobacco Control Act of 2009 declares 
that modified risk tobacco products must benefit the population as a whole considering both 
people who do and do not currently use tobacco products. Thus, regulators should be concerned 
if individuals who would otherwise not use tobacco become dependent upon ECIGs. This issue 
is particularly troublesome given high rates of ECIG use among adolescents and young adults 
(Audrain-McGovern, Stone, Barrington-Trimis, Unger, & Leventhal, 2019; Leavens, Stevens, 
Brett, & Leffingwell, 2019), which is a period particularly sensitive to development of nicotine 
dependence (Lanza & Vasilenko, 2015). The potential for otherwise non-tobacco using 
individuals to become dependent upon ECIGs may influence the consideration of modified risk 
status, marketing regulations, and warning labels placed upon ECIG companies. Similarly, 
regulators may need to develop information campaigns to ensure individuals, particularly youth, 
are aware of the possibility and implications of nicotine dependence. 
Chapter 2 - Method 
Selection of Participants 
 Participants were recruited through word-of-mouth and university-approved 
advertisements around the greater Morgantown area. Additionally, participants were recruited 
through internet websites such as Facebook and Craigslist. A total sample size of 10 experienced 
ECIG users was sufficient to detect effects for primary outcomes of subjective ratings (e.g., 
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craving, urge) and heart rate assuming a moderate to large effect size (Cohen’s f  > 0.25, Cohen, 
1988), a large correlation between repeated measures (r = 0.80), a desired power of 0.80, and a 
Type I error rate of 0.05.  
 Inclusion criteria. The ECIG-experienced participants recruited for this study must have 
self-reported a) use of a nicotine-containing ECIG for > 6 months, b) use < 10 cigarettes in the 
past year and c) use < 2 cigarettes in the past month. Current ECIG use was confirmed via a 
semi-quantitative urinary cotinine value > 3 (NicAlert®; Nymox Pharmaceutical Corporation, 
Quebec, Canada), while current non-smoking status was confirmed via an exhaled air carbon 
monoxide level < 5 ppm (Perkins, Karelitz, & Jao, 2013; Hiler et al., 2017). ECIGs are not a 
combustible product and do not generate carbon monoxide; therefore, the carbon monoxide level 
of ECIG users who do not smoke cigarettes should be akin to that of a non-smoker. Still, 
participants were required to use a nicotine containing ECIG, and thus cotinine levels, a 
metabolite of nicotine, should indicate nicotine use. No parameters were placed on other ECIG 
use characteristics due to the changing landscape of the ECIG market. While previous work 
required that participants use a specific amount of ECIG liquid daily at a specific concentration 
of nicotine (e.g., 1 ml/day of 12 mg/ml nicotine; Spindle et al., 2017), these criteria may no 
longer be viable. For instance, the popularity of “pod mod” systems have risen (Huang et al. 
2019), and such systems typically have a much higher nicotine concentration which may lead to 
a lower volume of liquid consumed per day relative to older devices. Juul pod mods, which 
account for over 40% of the ECIG market share (Huang et al., 2019), contain nicotine doses as 
high as 69-75 ml/mg (Eissenberg et al., 2018; Talih et al., 2019) and deliver pharmacologically 
active doses of nicotine in regular cigarette smokers (e.g., ~11 ng/ml plasma level) (Eissenberg 
et al., 2018). Recent work also reveals relatively high levels of nicotine in the urine of 
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adolescents aged 13-21 years who report current use of a pod mod system such as Juul  
(Goniewicz, Boykan, Messina, Eliscu, & Tolentino, 2018). Together with other work (Wagener 
et al 2017), users of a wide range of ECIG doses in combination with many different types of 
ECIGs may be consuming levels of nicotine that promote dependence. To maximize the 
likelihood of enrolling those who are dependent, participants also must have scored > 7 on the 
Penn State Electronic Cigarette Dependence Index (Foulds et al., 2015). From previous work 
with ECIG experienced users (Felicione et al., 2019) the median score on this index was 6 (range 
= 1 – 15). While this score is considered low – moderate (range = 0-20; Foulds et al., 2015), the 
reliability and validity of this scale has yet to be proven. Still, use of this cutoff ensures that we 
excluded ECIG users with the lowest levels of dependence. Finally, participants must have self-
reported an age of between 18 to 40 years, which should reduce the variability associated with 
age-related changes in withdrawal effects and cognition (Braver et al., 2001; Falcone et al., 
2014). 
 Exclusion criteria. Individuals were excluded if they reported an uncontrolled medical 
condition, a diagnosed psychiatric condition such as schizophrenia or bipolar disorder, regular 
use of most prescription medications (e.g., excluding vitamins and birth control), marijuana use 
> 10 days in the past 30 days, alcohol use > 25 days in the past 30 days, and use of other illicit 
substances in the past month. Women who reported breastfeeding or pregnancy, or tested 
positive for pregnancy via urinalysis, were excluded. These exclusionary criteria have been used 
successfully in other research with ECIG-experienced users (Ramôa et al., 2016; Spindle et al., 
2017). 
 Telephone screening procedure. Individuals who responded to advertisements were 
screened initially via telephone interview or an online screening questionnaire. Laboratory staff 
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read an approved transcript to explain the study procedures and requirements to interested 
callers. Interested individuals were asked to report on basic demographic, medical history, and 
drug use information (Appendix A). Individuals who appeared eligible based on this telephone or 
online screening were asked to visit the lab for an in-person screening (as in Blank et al., 2009; 
Felicione et al., 2019; Kleykamp et al., 2011; Spindle et al., 2017). Callers were told that the 
purpose of the study was to assess the short-term effects of ECIGs in order to better mask the 
purpose of the study to avoid participant expectation effects.  
 Informed consent & in-person screening procedures. Individuals were guided through 
the informed consent form to demonstrate study purpose, study procedures, potential risks and 
benefits of participation, and payment. Those who were willing and able to consent completed 
additional screening procedures. The laboratory screening visit consisted of questionnaires 
similar to those administered via the telephone interview (Appendix B-C). The purpose of these 
near-identical screening questionnaires was to ensure reliability of reporting, and individuals 
whose answers were conflicting were considered ineligible for participation. A trained staff 
member collected a urine sample from women to test for pregnancy (QuickVue, Quidel 
Corporation, San Diego, CA), as well as a urine sample from all potential participants to test for 
cotinine. Staff members also administered the Mini International Neuropsychiatric Interview 
(MINI) for Tobacco Use Disorder (Sheehan et al., 1998; Appendix D), which served as a clinical 
tool to determine the severity of tobacco dependence of participants. The MINI is a short 
diagnostic interview developed by clinicians and psychiatrists and associated with the DSM to 
diagnose tobacco use disorder, as well as other psychiatric disorders. Individuals who agreed to 
join the study and met the eligibility criteria for participation participated in a training session, 
and then scheduled their first study session.  
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Study Design 
 The study used a within-subjects design with two randomly-ordered sessions that differed 
by the duration of nicotine/tobacco abstinence: 0 (ad lib condition) or 180 min (abstinent 
condition). Participants were assigned to these two conditions using matched random assignment 
based on their percent correct for the RVIP task at baseline. Each session was approximately 3.5 
hours in length, and sessions were separated by a minimum of 48 hours (Kleykamp et al., 2011). 
Within each session, participants responded to a cognitive battery at two different time points, as 
well as subjective questionnaires every 30 min.  
 Training session. Participants practiced each cognitive task in a training session to 
minimize potential effects of practice (Mendrek et al., 2006). Specifically, participants 
completed an approximately two-hour practice session at the in-person screening visit, after they 
were determined to be eligible for this study. In this visit, the tasks were explained and 
demonstrated for participants, and participants completed practice versions of all three cognitive 
measures. Participants completed all cognitive tasks at least once, but no more than four times, 
during this training session. Training for a task was complete when the participant either: a) 
achieved greater than 70% accuracy, b) achieved consistent scores on repeated administration of 
a task, or c) achieved poorer performance with repeated administrations of a task. Previous 
reports suggest that three 30-min practice sessions can eliminate practice effects completely 
(Wesnes & Warburton, 1984), and other studies have condensed training into one, longer 
training session (McClernon et al., 2008). Participants were paid $10 upon completion of the 
training session. 
 Session procedure. All session procedures described below are outlined in Figure 1. As 
shown in this figure, both laboratory sessions began and ended at a consistent time and lasted 
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approximately 3.5 hours. Sessions began by collecting a breath sample to verify that CO < 5 
ppm. Continuous monitoring of heart rate commenced at the start of a session. The first 30 min 
of the session served as a habituation period to gather baseline physiological data and allow 
participants to become accustomed to the laboratory. Next, participants began a 5-min bout of 
ECIG puffing to standardize the time since last ECIG use. During this puffing bout, a research 
assistant instructed participants to take 10 puffs with a 30-sec interpuff interval (Blank et al., 
2009; Felicione et al., 2019). Participants then completed subjective questionnaires that assessed 
nicotine/tobacco withdrawal symptoms followed by a battery of cognitive tasks. Completion of 
this cognitive battery took approximately 20 min. In the abstinent condition, participants were 
not permitted to use an ECIG following the initial puffing bout. In the ad lib condition, 
participants were permitted to use their own ECIG ad lib throughout the session, with the 
exclusion of using the ECIG during the cognitive battery. Sessions were videotaped to 
characterize puff topography during the ad lib condition. 
 Thirty min following the completion of the initial puffing bout, subjective questionnaires 
were administered again. These same subjective questionnaires were measured every 30 min for 
180 min, with a total of 7 measurements. The cognitive battery was administered at one 
additional time during this same period, at 120 min. One hundred and twenty min was chosen as 
an assessment timepoint based on previous research demonstrating withdrawal-induced cognitive 
deficits within two hours of smoking abstinence (Hendricks et al., 2006; Parrott et al., 1996). 
Participants were permitted to eat lunch during the session, though all food and beverages were 
required to be caffeine-free. Caffeine may improve performance on cognitive measures such as 
sustained attention/vigilance tasks (for review, see Smith, 2002) and thus, may confound results 
if consumed during sessions. Throughout the session, participants were allowed to engage in 
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activities with a low cognitive load (e.g., watch movies, play games of phone, read book), but 
were not permitted to engage in tasks that involve a high cognitive load (e.g., writing an essay), 
Participants were paid 60 dollars at the completion of each session (plus 10 dollars at training), 
for a total amount earned of 130 dollars. 
Materials 
 ECIG devices. Participants were required to use their own ECIG liquid and device 
combination, as opposed to standardizing these features (as in Spindle et al., 2017). The ECIG 
market is currently inundated with innumerable combinations of liquid flavors, solvents, and 
nicotine concentrations, as well as battery voltage and atomizer resistance levels. Thus, not only 
it would be nearly impossible to choose a single best combination of these features, but 
generalizability would also be limited. Moreover, our previous work demonstrates that use of a 
standardized ECIG liquid/device by experienced ECIG users may prevent product consumption 
during the ad lib condition. That is, some participants who found the standardized product to be 
less than satisfactory, based on spontaneous verbal reports and/or ratings on questionnaires 
related to sensory cues or withdrawal suppression, failed to engage in ECIG use during one or 
more ad libitum puffing bouts. Importantly, a small sample of the liquid used by participants was 
collected for later analysis to confirm that the nicotine concentration is at least 3 mg/ml nicotine. 
 Computer equipment. All cognitive tasks were administered via the E-Prime 3.0 
computer software (Kleykamp, Jennings, Blank, & Eissenberg, 2005; Schneider, Eschman, & 
Zuccolotto, 2002). Subjective questionnaires were administered via computerized software 
(Clinical Research Support Systems). Physiological data was recorded through the same software 
as subjective questionnaires. 
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 Video equipment. A Canon Vixia HF R42 (Canon USA, Inc.; Melville, NY) was used to 
record ECIG use for ad lib conditions. This video camera has been used successfully to record 
ECIG puffing bouts in previous research (Felicione et al., 2019). The video data was imported to 
and analyzed in Adobe Premier Pro 2015 (Adobe Systems, Inc.; San Jose, CA).  
Primary Outcome Measures 
 Primary outcome measures were heart rate and subjective ratings of withdrawal and 
nicotine effects. An additional primary outcome included dependence characteristics of 
individuals that completed a telephone screening. 
 Heart rate. Heart rate was measured continuously throughout each session (Noninvasive 
Patient Monitor model 506 NP3, Criticare Systems, Inc., Waukesha, WI). Heart rate was 
captured via finger pulse oximeter that can capture a range of 20 to 300 beats per min with an 
update time of one sec and an accuracy of +/- one beat per min or one percent of the reading 
(Criticare Systems, Inc.). Heart rate was collected every 20 sec and then transferred to a 
computer. Heart rate data were averaged into 5-min bins to create single values at each 30-min 
timepoint. Measurement of heart rate served multiple purposes. First, changes in heart rate are 
indicative of exposure to nicotine (Hendricks et al., 2006; Jolma, Samson, Klewer, Donnerstein, 
& Goldberg, 2002; Omvik, 1996). Second, heart rate was used to monitor participant safety, and 
a medical monitor was contacted if a participant’s vital signs fall out of a predetermined ranged 
(see subsection Participant Safety and Rights). These materials and methods for collecting 
physiological data have been used to maintain data integrity and participant safety in both 
cigarette smokers (Blank et al., 2009; Breland et al., 2002; Cobb, Shihadeh, Weaver, & 
Eissenberg, 2011) and ECIG users (Felicione et al., 2019; Spindle et al., 2017). 
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Minnesota nicotine withdrawal scale. The Minnesota Nicotine Withdrawal Scale 
(MNWS; Hughes & Hatsukami, 1986) questionnaire (Appendix E) is a measure of nicotine and 
tobacco withdrawal symptoms. The questionnaire contains 11 items: “Urges to smoke,” 
“Irritability/frustration/anger,” “Anxious,” “Difficulty concentrating,” “Restlessness,” “Hunger,” 
“Impatient,” “Craving a cigarette/nicotine,” “Drowsiness,” “Depression/feeling blue,” and 
“Desire for sweets”. Items specifically related to cigarettes (“Craving a cigarette/nicotine”) were 
adapted to electronic cigarettes. Participants were shown the word or phrase centered above a 
horizontal line serving as a visual analog scale. The left end of the line showed the phrase “not at 
all” (score = 0), and the right end of the line showed the phrase “extremely” (score = 100). 
Participants moved the cursor to any point of the line and click to create a vertical mark, which 
could be moved before the participants continues to the next question. Each score was expressed 
as a percentage of the total line length from the left end to the vertical mark. Internal consistency 
for this measure has not been assessed, however, the items are known to be valid and reliable 
indicators of withdrawal symptoms (Hughes & Hatsukami, 1986; Hughes, 2007b). This 
questionnaire has been commonly used to assess withdrawal symptoms in cigarette smokers 
(Blank et al., 2009; Breland, Kleykamp, & Eissenberg, 2006; Bullen et al., 2010; Cobb et al., 
2011; Wagener et al., 2014) and more recently, in ECIG users (Felicione et al., 2019; Spindle et 
al., 2017; St. Helen et al., 2016) 
 Tiffany-Drobes questionnaire of smoking urges: brief form (QSU-Brief). The QSU-
Brief (Appendix F, Cox, Tiffany, & Christen, 2001; Tiffany & Drobes, 1991) consists of 10 
Likert-scale items measuring multidimensional features of nicotine and tobacco cravings. 
Statements (e.g., “All I want right now is a cigarette”; “I am going to smoke as soon as 
possible”) were presented above seven boxes, with the leftmost labeled “strongly disagree” 
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(score = 0) and the rightmost labeled “strongly agree” (score = 6). Participants moved the cursor 
to select one box, which could be adjusted before continuing to the next item. Like the MNWS, 
statements were adapted by replacing “cigarette” and “smoke” with “ECIG” and “vape”, 
respectively. Items were collapsed into two factors previously defined by factor analysis: 
intention to smoke (scale range = 0-30) and anticipation of relief from withdrawal (scale range = 
0-24). The QSU-Brief has demonstrated high reliability (Cronbach’s alpha = 0.97, Cox et al., 
2001) and internal consistency within each of the two factors (Cronbach’s alpha = 0.96, 0.92; 
Cox et al., 2001). The QSU and QSU-Brief are common measures of nicotine and withdrawal 
symptoms in cigarette smokers (Blank et al., 2009; Breland et al., 2006; Cobb et al., 2011; 
Norton, June, & O’Connor, 2014) and ECIG users (Felicione et al., 2019; St. Helen et al., 2016; 
Vansickel & Eissenberg, 2013). 
 Direct effects of nicotine scale (DENS). The DENS (Appendix G; Evans, Blank, Sams, 
Weaver, & Eissenberg) is a 10-item VAS that assesses the intensity of nicotine-associated side 
effects. The questionnaire items include “nauseous,” “dizzy,” “lightheaded,” “nervous,” 
“sweaty,” “headache,” “excessive salivation,” “heart pounding,” “confused,” and “weak.” This 
questionnaire has been used to assess nicotine effects associated with ECIG use (Felicione et al., 
2019; Hiler et al., 2017; Spindle et al., 2017). 
 Direct effects of product scale (DEPS). The DEPS (Appendix H) is a 9-items VAS to 
assess effects commonly associated with cigarette smoking, but were modified to ask about 
vaping. Questions began with the prompt “was the product…” or “did the product…” followed 
by “satisfying,” “pleasant,” “taste good,” “make you dizzy,” “calm you down,” “help you 
concentrate,” “make you feel more awake,” “reduce your hunger for food,” and “make you 
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sick?” Similar to the DENS, this questionnaire has been used to assess effects of vaping after 
bouts of ECIG use (Felicione et al., 2019; Hiler et al., 2017; Spindle et al., 2017). 
 ECIG dependence and use. All individuals that completed a telephone/online screening 
were asked questions about their cigarette use history (lifetime, past year, past month), as well as 
ECIG use history and ECIG dependence (see specific items in Appendix A). Specifically, 
screening questionnaires included information about a) ECIG device and liquid specifications 
(e.g., model, liquid nicotine concentration, flavor, wattage), b) amount of liquid used (ml/day), c) 
frequency (days/week) and duration (months/years) of ECIG use, and d) ECIG dependence 
(Penn State Electronic Cigarette Dependence Index). Regarding enrolled participants, study staff 
observed participants’ ECIG devices and liquid to verify the specifications reported by the 
participant at screening. 
Secondary Outcome Measures 
 Secondary outcomes included those related to cognitive processing – attention, working 
memory, and inhibitory control – and also the reinforcing efficacy of ECIGs (choice). Additional 
secondary outcomes included characterizing puff topography in the ad lib condition. 
 Rapid visual information processing task (RVIP). The RVIP is one of the most 
frequently used tasks of sustained attention among smokers (Wesnes & Warburton, 1983). This 
task involves a series of single digits being presented on a computer screen at a rapid pace. 
Participants were instructed to press a response key when they noticed three consecutive odd 
digits or three consecutive even digits. This task has been used extensively to measure 
abstinence-induced deficits in attention in cigarette smokers (Gilbert et al., 2005; Hendricks et 
al., 2006; McClernon et al., 2008; Wesnes & Warburton, 1983; Wesnes & Warburton, 1984). 
Specifically, research has demonstrated that smokers may show accuracy reduction and slowed 
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reaction time for sustained attention tasks at 2 hours of deprivation, with peak effects at 6 hours 
(Parrott et al., 1996).  
 As depicted in Figure 2, digits were presented in the center of a computer screen at a rate 
of 100 digits per min (Gilbert et al., 2005; Hendricks et al., 2006) for approximately 6 min. 
Previous research has included a 9-min version of this task (Gilbert et al., 2005; McClernon et 
al., 2008), though differences between abstinent and non-abstinent smokers have been detected 
within the first 4 min (Herbert, Foulds, & Fife-Schaw, 2001). Response targets were set to 
appear eight times per min, with 5 to 30 digits appearing between each target (Hendricks et al., 
2006). The window in which participants must respond lasted 1500 milliseconds (ms), though 
digits continued to appear at a constant rate (Hendricks et al., 2006; Herbert et al., 2001), and the 
response was the press of a computer key. Specifically, participants were asked to press the key 
after each sequence of three consecutive odd or even digits (e.g., 7-3-1, or 2-8-6).  
The RVIP task yielded four dependent variables. Correctly identified targets (measured 
via “percent correct”) were defined as a press on the response key when three consecutive odd or 
even digits are presented. Reaction time to targets (measured in ms) was defined as the latency to 
press the response key when three consecutive odd or even digits are presented. Errors of 
commission (measured via number of incorrect responses) were defined as a press on the 
response key when there was not three consecutive odd or even digits presented (“false 
positive”). Finally, errors of omission (measured via number of missed targets) were defined as a 
lack of a press on the response key when three consecutive odd or even digits are presented 
(“false negative”; Hendricks et al., 2006).  
 N-back task. The n-back task (Jonides et al., 1997) served as a cognitive assessment of 
working memory. The 2-back and 3-back version of this task was used (Kleykamp et al., 2005; 
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Kleykamp et al., 2011), as previous research has revealed no differences between satiated and 
abstinent smokers for 0-back and 1-back versions (Mendrek et al., 2006). The n-back task 
involved a block of trials with a 45-letter sequence presented to subjects. Each letter was 
presented in the center of a blank screen for 500 ms, with a 2.5-sec interstimulus interval 
(Jonides et al., 1997; Falcone et al., 2014; Myers et al., 2008). The 45-letter sequence was 
designed so that there are 14 letters that correctly match the n-back target. Each time the n-back 
task was measured, participants responded to one block for the 2-back condition and one block 
for the 3-back condition. Completion of the n-back task took approximately 4.5 min. 
For the 2-back condition (see Figure 3, Panel A), participants first saw the instruction 
“Find 2-back.” They were required to press the “yes” key when the letter presented was identical 
to the letter displayed two letters prior (e.g. A-B-A), and not respond when the letter presented 
was different from the letter displayed two letters prior (e.g., A-B-C). Procedures for the 3-back 
condition mimicked the 2-back condition, except the 3-back condition involved identifying the 
target letter that is displayed 3 letters prior (e.g., A-B-C-A) (see Figure 3, Panel B). The n-back 
task has been used readily in assessing cognitive performance of cigarette smokers (Mendrek et 
al., 2006; Kleykamp et al., 2011)  
There were two dependent variables associated with the n-back task: accuracy and 
reaction time to correct “yes” responses. Accuracy was defined as the proportion of hits minus 
the proportion of false positives. A hit is a correctly identified n-back target (e.g., A-B-A for 2-
back, A-B-C-A for 3-back) and a false positive is a response that does not match the n-back 
condition. Reaction time to correct “yes” responses (measured in ms) is defined as the latency to 
respond when the participant correctly identifies an n-back target. These variables will be 
analyzed separately for the different n-back conditions. 
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 Cued go/no-go task. The Cued Go/No-Go task is a behavioral measure of inhibitory 
control, testing a participant’s ability to respond when appropriate and to withhold a response 
when no response is required (McClernon et al., 2015). The Go/No-Go task for the proposed 
study was based on a method used to assess effects of caffeine and alcohol (Marczinski & 
Fillmore, 2003), as well as smoking abstinence (Harrison et al., 2009; McClernon et al., 2008). 
Figure 4 depicts the Cued Go/No-Go task. Each trial began with the presentation of a 
cross in the center of the screen on which participants were asked to fixate their attention. This 
“fixation cross” was presented for 800 ms followed by a blank screen for 500 ms. After the blank 
screen, a cue was presented in the center of the screen for 100, 200, 300, 400, or 500 ms. The 
cue, a white rectangle with a black outline, alternated from being in a vertical or horizontal 
orientation for each of 50% of trials. A vertically-presented rectangle was indicative of an 
upcoming “go” target, while a horizontally-presented rectangle was indicative of an upcoming 
“no-go” target. After the cue was presented for the pre-defined length of time, it changed from 
white to either blue or green (for printing purposes, blue is represented as gray and green is 
represented as black in Figure 4). In trials when the rectangle became green, the participant must 
press the response key as quickly as possible (go trial). In trials when the rectangle became blue, 
the participant must withhold a response (no-go trial). The cue appeared on the screen for 1000 
ms, or until the participant made a response. Cues may have been correct or incorrect. For 
example, on 80% of trials, the orientation of the rectangular cue correctly informed the 
participant about the type or target that will follow (i.e., vertical and green, horizontal and blue). 
For 20% of the trials, the cue and the target were incongruent (i.e., horizontal and green, vertical 
and blue). A total of 250 trials were presented over 5 blocks. The variable and random duration 
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of the cue, along with the 80% probability of a congruent cue and target, may have prevented 
participants from anticipating the upcoming cue (Marczinksi & Filmore, 2003). 
There were three dependent variables associated with the cued Go/No-Go task: response 
inhibition for correctly cued trials, response inhibition for incorrectly cued trials, and response 
execution. Response inhibition (measured via “percent correct”) was defined as the proportion of 
correct non-responses to no-go trials. Response inhibition was calculated separately for correctly 
cued trials (No-Go accuracy when the rectangle orientation and color change are consistent) and 
incorrectly cued trials (No-Go accuracy when the rectangle orientation and color change are 
inconsistent). Response execution (measured in ms) was defined as the latency to respond on go 
trials (Marczinski & Fillmore, 2003; McClernon et al. 2008). 
  Multiple choice procedure. The Multiple Choice Procedure (MCP; Appendix I) is a 
validated method to assess the abuse liability of a drug for a human in a laboratory setting 
(Grffiths, Triosi II, Silverman, & Mumford, 1993; Griffiths, Rush, & Puhala, 1996). This 
procedure involves a participant making choices of a preference for a drug or increasing amounts 
of money. Specifically, this task included 10 trials in which participants chose between a fixed 
level of ECIG use (10 ECIG puffs) or increasing amounts of money ($0.01, 0.02, 0.04, 0.08, 
0.16, 0.32, 0.64, 1.28, 2.56, 5.12). The dependent variable for this task was the crossover point, 
or the trial at which a participant switched from choosing 10 puffs to an amount of money. This 
procedure has been used to assess the abuse liability of a variety of drugs, including ECIGs 
(McPherson et al., 2016; Vansickel, Weaver, & Eissenberg, 2012).   
 Puff topography. Puff topography served as the primary measure of ECIG consumption. 
Puff topography variables that can be measured via video include puff number (the amount of 
puffs), puff duration (the length of a puff, measured in sec), and interpuff interval (IPI, the time 
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between puffs, measured in sec). Ad lib sessions were videotaped and scored by two independent 
raters to determine puff number, puff duration, and IPI throughout the session. The operational 
definitions used for these variables are based on our previous work that evaluated the reliability 
and validity of measurement methods for ECIG puff topography (Felicione et al., 2019). Puff 
duration was defined as the amount of time between the first frame in which a participant’s lips 
are enclosed around the ECIG until the last frame in which their lips remain enclosed around the 
ECIG. IPI was defined as the amount of time between the first frame in which a participant’s lips 
are removed from the ECIG (e.g., first frame after a puff ends) until the last frame before the 
next puff starts. Puff number was defined as the number of puffs that are > 300 ms with an IPI > 
300 ms. Puffs with < 300 ms IPIs were collapsed into one puff, and any remaining puffs < 300 
ms durations were deleted (similar to Felicione et al., 2019; Hiler et al., 2017; Spindle et al., 
2017) 
Currently, there is no accepted definition of a single ECIG use bout (for review, see 
Blank et al., 2016). Recent work (St. Helen et al., 2016), however, has attempted to characterize 
such bouts using “puff clusters,” or the number of puffs with no more than 60 sec between each 
puff (< 60 sec IPI). These clusters can be further categorized by the number of puffs in a cluster: 
short (2 – 5 puffs), medium (6 – 10 puffs) and long (> 10 puffs). We modeled this approach 
using topography data from the ad lib session. All video-based topography variables were scored 
by two independent raters and compared for assessment of interrater reliability.  
Participant Safety and Rights 
 Participant’s safety and rights were assured through an IRB-approved protocol enacted 
by trained laboratory staff. Participants were made aware of the Office of Research Integrity and 
Compliance and the fact that they can contact this office with questions about their rights as a 
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participant. Participants were not expected to incur adverse events, given that they are 
experienced ECIG users and will be using their own ECIG to puff throughout the session. 
Participants were warned that they may experience aversive withdrawal symptoms from tobacco 
abstinence such as irritability, anxiety, and restlessness (Hughes & Hatsukami, 1986; Rubinstein, 
Benowitz, Auerback, & Moscicki, 2009). These withdrawal effects may cause discomfort; 
however, they are not medically dangerous. To ensure safety throughout the session, 
physiological measure of heart rate and blood pressure were monitored continuously. A medical 
monitor would have been contacted regarding participant safety if heart rate exceeds the range of 
50 to 110 bpm, though this issue never occurred. Confidentiality was assured by using coded 
identity numbers for participant data and storing data in locked room and on password protected 
computers. 
Data Preparation and Analysis 
 Data preparation. Data for the cognitive tasks and ECIG puff topography was prepared 
based on the dependent variables described above. Heart rate data was averaged into 5-min bins 
to create single values at each 30-min time point, for a total of 8 values. 
 Feasibility and recruitment. Feasibility of the method was explored by examining 
enrollment and attrition rates. This descriptive analysis included assessing the number of 
participants screened, enrolled, and completing the study. Also reported were reasons for 
ineligibility and baseline characteristics (e.g., age, cigarette and ECIG use, ECIG dependence) of 
all callers, those deemed ineligible, those deemed eligible, and study completers. Characteristics 
of those ineligible versus eligible were compared using inferential statistics (e.g., chi-square, 
independent samples t-tests).  
ACUTE ABSTINENCE EFFECTS OF ECIG USERS 36 
 Predictors of ECIG dependence. Data from the telephone screening questionnaire were 
used to assess the ECIG use characteristics that may predict ECIG dependence. This 
questionnaire included items regarding cigarette use, ECIG use and ECIG dependence. A 
multiple linear regression was used for this aim to determine if ECIG dependence can be 
predicted based on these characteristics. Variables were examined to ensure they meet the 
assumptions of regression. First, variables were investigated for acceptable skew and kurtosis, 
using standards of <3.2 for skew/standard error skew (Zskew) and <3.2 for Zkurtosis (Kim, 
2013). Variables were also assessed for a normal distribution through visual inspection of 
histogram. Next, z-scores for each variable were assessed to determine univariate outliers. Cases 
with z-scores >3.2 that seemed to be unrealistic were truncated or removed. When variables were 
not normally distributed, log and square root transformations were used, and the distribution was 
reassessed. Predictor variables also were investigated for their correlation with PSECDI scores 
and scatterplots between these variables were viewed to determine if there was a linear 
relationship. Finally, multicollinearity was assessed with the Variance Inflation Factor (VIF). 
Common rules of thumb have been that VIF > 10 or > 4 are problematic, however, there is no 
ideal standard that applies to all analyses (O’Brien, 2007). 
All predictor variables initially considered for the model were continuous variables, 
including duration of use (months), frequency of use (days/week), liquid consumption (ml/day), 
nicotine concentration (mg/ml), device power (watts), and lifetime cigarette use. Age was 
included as a covariate in the model. All variables were entered into the model simultaneously. 
Significance of the full model and of individual predictors was determined at p < 0.05. 
Specifically, the F-statistic (p < .05) was reported to determine significance of the full model. R2 
was reported to explain how much variance in ECIG dependence can be accounted for by the 
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model. Standardized beta coefficients were reported for individual predictors, which were 
considered significant predictors at p < 0.05. An iterative approach to model assessment was 
used, in which the predictor with the largest p-value was removed and the model was run again. 
This approach was used until all individual predictors in the model were significant. Model fit 
was compared using the Akaike information criterion (AIC), with the lowest AIC value 
indicating the best model fit.  
Based on previous research, it was hypothesized that all predictor variables would be 
positively associated with nicotine dependence. Frequency of use and duration of use were likely 
to be the strongest predictors given their reliable association with ECIG dependence. However, 
variables that influence nicotine delivery, such as nicotine concentration, device power, and 
liquid consumption may have complex interactions that limit their predictive validity as a single 
variable in the model. For example, individuals that use lower nicotine concentrations tend to 
vape at higher wattages and consume more liquid than individuals using higher nicotine 
concentrations (Smets et al., 2019). 
 Primary outcomes. Subjective and heart rate data were analyzed using a 2 (condition: ad 
lib, abstinent) x 7 (time, 8 for heart rate) repeated measures ANOVA. Huynh-Feldt corrections 
were used to adjust for violations of sphericity (Huynh & Feldt, 1976). Differences between 
means were examined using Tukey’s Honestly Significant Difference (HSD; Keppel, 1991) and 
were reported significant at p < .05 level. It was hypothesized that withdrawal symptoms and 
heart rate will be lower, and nicotine effects will be higher, in the abstinent condition than the ad 
lib condition. Additionally, these effects are expected to change over time in the abstinent 
condition while remaining stable in the ad lib condition. 
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 Secondary outcomes. Secondary outcomes were explored primarily with descriptive 
analyses rather than ANOVAs due to the limited power to detect significant differences 
associated with a small sample size. Secondary outcomes include cognitive tests (RVIP, n-back, 
Cued Go/No-Go) and the MCP. Additional descriptive analyses included percent change from 
time 0 for cognitive outcomes.  
Two paired-samples t-tests were used for cognitive outcomes and the MCP to make 
planned comparisons (p < 0.05). Specifically, one t-test was used to compare the abstinent and 
ad lib conditions at 120 min, and one t-test was used to compare the abstinent group at 0 min 
(baseline) and 120 min. Both of these comparisons provided information regarding possible 
abstinence-induced cognitive changes and were used to generate effect sizes to inform future 
research. To correct for multiple comparisons, the False Discovery Rate procedure was used 
(Benjamini & Hochberg, 1995). This procedure reduces the likelihood of making a Type I error 
by controlling for the expected proportion of false positives out of all rejected null hypothesis. 
This procedure may increase power to detect significant differences as compared to more 
conservative approaches such as the Bonferroni correction. The False Discovery Rate (FDR) 
procedure involved ranking all statistical tests followed by the determination of a new critical 
value for each test. It was hypothesized that cognitive performance would be poorer and MCP 
crossover point would be higher at 120 min of abstinence compared to baseline abstinence or 
120 min ad lib ECIG use. Additionally, means and standard deviations were reported for session 
1 and session 2 to determine if order effects may have influenced results.   
Puff topography. Puff topography was characterized using puff number, puff duration, 
and IPI. Two independent raters scored these variables for each ad lib session. Interrater 
reliability was assessed for puff duration and IPI using two-way random Intraclass Correlation 
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(ICC) for consistency among average measures, with values > 0.90 being considered reliable. 
Interrater reliability was determined for puff number using Fleiss’ Kappa for Interrater 
agreement. 
Puff topography was characterized according to puff clusters according to a definition 
from recent work (St. Helen et al., 2016). This analysis was a way of assessing how individual 
puffs group together, rather than solely assessing each puff alone. Specifically, a puff cluster was 
defined as the number of puffs with no more than 60 sec between each puff (< 60 sec IPI). These 
clusters were further categorized by the number of puffs in a cluster: short (2 – 5 puffs), medium 
(6 – 10 puffs) and long (> 10 puffs). We modeled this approach using topography data from the 
ad lib session. Additional variables of interest were total puff number, average puff durations, 
average IPIs, the percent of total puffs within a session by cluster type, the number of puffs 
within each cluster type, and the IPI and number of puffs between clusters and the following up. 
Individual patterns of puffs also were examined for three participants that demonstrated different 
patterns. Video errors led to the loss of topography data for two participants.  
Predicting withdrawal from puff topography. Puff topography variables were used to 
determine if topography is predictive of withdrawal outcomes. Specifically, the number of puffs, 
puff clusters, and average puff duration and IPI were measured for each 30-min timepoint (e.g., 0 
– 30 min, 30 – 60 min, etc.). Multiple linear regressions were used to determine if these 
topography variables could predict primary outcomes (subjective withdrawal, nicotine effects, 
heart rate). Significance of the full models and of individual predictors was determined at p < 
0.05. Specifically, the F-statistic (p < .05) was reported to determine significance of the full 
model. R2 was reported to explain how much variance in ECIG dependence can be accounted for 
by the model. Standardized beta coefficients were reported for individual predictors, which was 
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considered significant predictors at p < 0.05. It was hypothesized that larger puff numbers and 
longer puff durations will be associated with lower subjective withdrawal, higher nicotine 
effects, and higher heart rate. 
Chapter 3 - Results 
 
Feasibility and Recruitment 
 Figure 5 demonstrates progress across the study phases of screening, enrollment, and 
completion. Of 178 individuals who called the laboratory and completed a telephone screening 
questionnaire, 41 (23.03%) were deemed eligible. While 22 (53.66%) of these 41 individuals 
were enrolled (i.e., consented), 15 (36.58%) passed the in-person screening and actually began 
the study. Eleven of these 15 participants (73.33%) completed the entire protocol. Also shown in 
this figure are reasons for ineligibility at telephone screen, with the most common reasons being 
PSECDI < 7 (41.61%; Mscore = 3.61, SD = 2.15), past month marijuana use > 10 (32.12%), and 
past year cigarettes > 10 (20.44%). [Note that these reported percentages do not exclude 
participants also ineligible for other reasons.] Twenty-five callers (18.25% of all callers, 43.86% 
of callers excluded for PSECDI < 7) were excluded for low PSECDI scores alone. These reasons 
for ineligibility were also the most common based on the in-person screening, with responses for 
PSECDI scores and marijuana use changing so that participants were no longer eligible. There 
were a large number of scheduled screenings and sessions that were not attended (37.14% and 
40.48%, respectively). 
 Table 3 demonstrates demographic, cigarette use, and ECIG use characteristics for all 
callers (n = 178), ineligible callers (n = 137), eligible callers (n = 41), and completers (n = 11). A 
lower percentage of eligible callers were lifetime cigarette smokers compared to ineligible callers 
(X2(1)= 4.15, p < .05). Those who were eligible for the study had higher PSECDI scores [t(169) 
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= 3.08, p < .01] and used ECIGs more days/week [t(169) = 2.08, p < .05] than ineligible callers, 
though these groups did not differ significantly on any other characteristic (t’s < 1.66, X2’s < 
3.24, p’s > .05). 
Screened callers. Overall, callers were mostly young adults (M = 20.96 years, SD = 
4.14), and primarily nonsmokers (< 100 cigarettes lifetime, 72.60%). Most callers were daily 
ECIG users and preferred mint/menthol (46.5%) and fruit (25.3%) flavors. There was a high 
percentage of users of 4th generation pod ECIGs (76.69%; with 60.74% reporting use of Juul 
specifically), which may account for the relatively high nicotine concentrations reported by the 
sample (M  = 42.14 mg/ml; mode and median = 59 mg/ml). Indeed, for 4th generation relative to 
2nd/3rd generation device users, higher nicotine concentrations [M(SE) = 54.43 (1.06) vs. 7.37 
(1.33) mg/ml; t(161) = -22.81, p < .001], less liquid ml/day [0.65 (0.07) vs. 6.53 (1.10) ml; t(159) 
= 5.31, p < .001)], lower propylene glycol percentages [30.69% (0.37) vs. 43.50% (3.66); t(136) 
= 3.48, p < .001], and lower wattages [11.16 (1.42) vs 70.61 (3.99) watts; t(155) = 13.97, p < 
.001] were reported. Flavor preferences also differed by device type, with mint (60.80%) and 
fruit (20.80%) being the most common flavors in 4th generation users and fruit (53.57%) and 
sweet/dessert (46.43)% being preferred among 2nd /3rd generation users, X2(5) = 62.59, p < .001.  
These 4th generation users were also younger [19.84 (0.24) vs. 24.18 (1.09) years, t(161) = 4.15, 
p < .001] and had a smaller percentage of lifetime smokers (22.76% vs. 42.11%; X2(1) = 5.47, p 
< .05. However, these 4th generation users also did not use ECIGs for a significantly shorter 
duration than 3rd generation users [16.39 (2.47) vs. 23.84 (2.95) months; t(160) = 1.55, p > .05], 
or have significantly lower dependence scores [8.20 (0.41) vs. 9.18 (0.70); t(169) = 1.18, p > 
.05]. 
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Study completers. Table 4 shows data for these and additional characteristics for 
completers, based on the information collected at the in-person screening visit only. 
Characteristics of completers were similar to that of all callers, though there was a higher 
percentage of nonsmokers (90.90%) and higher PSECDI scores (M = 11.91, SD = 3.30) for 
completers. All participants met the clinical definition of tobacco use disorder based on the 
MINI, with most participants classified as severely dependent (63.6%), and others being split 
evenly between moderately (18.2%) and mildly (18.2%) dependent. These categorizations differ 
somewhat from those for the PSECDI, in which 36.4% had high dependence, 45.5% had medium 
dependence, and 18.2% had low dependence. Additionally, 36.37% of participants had a higher 
MINI severity than PSECDI severity, with three of four of these participants deemed severe by 
MINI but moderate by PSECDI. In contrast, 18.18% had higher PSECDI severity than MINI 
severity, and 45.45% were classified the same by the two measures. There was not a significant 
correlation between PSECDI scores and the number of MINI symptoms, r(9) = 0.55, p = .08.  
Similar to the sample of all callers, completers who used 4th and 3rd generation devices used 
different nicotine concentrations [56.63 (6.72) vs. 4.00 (1.73) mg/ml], wattages [8.00 (0.00) vs. 
70.00 (17.32) watts], liquid use [0.55 (0.26) vs 8.00 (3.46) ml/day] and duration of use [1.05 
(0.47) vs. 3.67 (2.08) years]. The higher proportion of 4th generation users explains the higher 
nicotine concentration (42.27 mg/ml) among completers, though liquid use/day and wattage 
values are elevated due to the much higher levels among 3rd generation users.  
Predictors of Dependence 
 A multiple linear regression was used to determine if cigarette and ECIG use can predict 
ECIG dependence in the sample of 178 individuals screened via telephone. Initial predictors 
considered for the model were lifetime cigarette use, ECIG nicotine concentration (mg/ml), 
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frequency of ECIG use (days/week), quantity of ECIG use (ml/day), duration of ECIG use 
(months), and device power (watts). Table 5 includes information regarding descriptive statistics 
for predictor variables and their correlation with PSECDI scores. Additional details regarding 
exploration and handling of variables, associations with dependence, and considered interactions 
between variables are presented in Appendix J.  
 As shown in Table 6, multiple linear regression models were run to predict PESCDI 
scores based on smoking status (dichotomous), nicotine concentration (continuous), daily use 
(dichotomous), log-transformed liquid/day (continuous), square root-transformed duration of use 
(continuous), log-transformed wattage (continuous) and log-transformed age (continuous) as a 
covariate. AIC was used to compare how well the models fit the data, with lower AICs being 
favorable. At each step, while the overall model was significant, not all individual predictors 
significantly predicted PSEDCI scores and models were rerun removing the predictor with the 
highest p-value. In model 1, VIF was 5.09 for nicotine concentration and 3.94 for wattage, which 
indicated the possibility for problematic multicollinearity. Due to this concern of 
multicollinearity, the model was rerun removing nicotine concentration alone (Model 2) and 
wattage alone (Model 3). Model 2 had a lower AIC than model 3 which indicated a better fit to 
the data, so subsequent models were run based on Model 2. In subsequent models, liquid use was 
removed (Model 4), nicotine concentration was removed (Model 5), and smoking status was 
removed (Model 6). In this final model, both remaining variables significantly predicted PSECDI 
scores, with daily ECIG use and longer duration of ECIG use being associated with higher 
dependence. However, as variables were being removed, models had higher AICs, demonstrating 
a worse fit. One additional model was attempted (Model 7), removing smoking status (variable 
with highest p-value) from model 1. The AIC for Model 7 was higher than for Model 1, so 
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Model 1 was determined to best fit the data. In Model 1, increased age, nicotine concentration, 
daily ECIG use, duration of ECIG use, and wattage were significantly associated with higher 
ECIG dependence. However, beta weights and standard errors for nicotine concentration and 
wattage should be interpreted with caution this model should be interpreted with caution due to 
potential multicollinearity issues.   
Heart Rate 
 Table 7 shows main effects and interaction results from repeated-measures ANOVAs for 
heart rate and subjective outcomes. There was a significant main effect of condition and of time 
for heart rate. Specifically, heart rate was significantly lower in the abstinent condition (M = 
73.59, SE = 1.76) than in the ad lib condition (M = 78.59, SE = 2.15). For the main effect of 
time, heart rate at baseline (post-directed bout, M = 86.11, SE = 2.17) was significantly greater 
than all other timepoints: pre-directed (M = 77.32, SE = 1.75), 30 min (M = 76.03, SE = 1.88), 60 
min (M = 74.25, SE = 1.94), 90 min (M = 75.00, SE = 2.19), 120 min (M = 74.23, SE = 2.26), 
150 min (M = 72.60, SE = 1.57) and 180 min (M = 72.95, SE = 1.94) (Tukey’s HSD; p < .01). 
Figure 6 demonstrates heart rate over time for both sessions.  
Subjective Questionnaires 
 MNWS. A significant condition x time interaction was observed for craving (F = 4.04, p 
< .05; Figure 7). Post-hoc tests revealed that ratings of craving were lower at baseline (M = 
20.09, SE = 5.51) than at 120 min (M = 55.73, SE = 8.49, p < .05), 150 min (M = 64.09, SE  = 
8.39), and 180 min (M = 68.91, SE = 8.08, p’s < .01) within the abstinent condition, but not 
lower than 30 min (M = 28.55, SE  = 7.20), 60 min (M = 38.64, SE = 7.45) or 90 min (M = 43.09, 
SE = 7.32). No significant differences were observed across timepoints within the ad lib 
condition, or between conditions. A similar pattern was observed for urges, which was also 
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significant for condition x time (F = 2.53, p < .05). Post-hoc tests revealed that ratings of urges at 
baseline (M = 24.36, SE = 7.13) were significantly lower than at 120 min (M = 54.36, SE = 8.82), 
150 min (M = 65.18, SE = 9.01) and 180 min (M = 69.36, SE = 8.07, p’s < .01) in the abstinent 
condition, but not lower than 30 min (M = 40.09, SE = 7.26), 60 min (M = 38.55, SE = 6.78) or 
90 min (M = 48.91, SE = 7.93). Additionally, urges were significantly different at 180 min 
between the abstinent and ad lib conditions (M = 37.36, SE = 7.62, p < .01). Also observed were 
significant main effects of time for the items difficulty concentrating, impatient, and irritable 
(F’s > 3.21; p’s < .05); however, post-hoc tests revealed that these effects were not reliable. For 
impatient, for instance, the item with the largest F value for the main effect of time, baseline 
values (M = 8.32, SE = 2.68) were not significantly lower than at 30 min (M = 17.45, SE = 4.25), 
60 min (M = 13.82, SE = 3.45), 90 min (M = 15.05, SE = 4.16), 120 min (M = 19.91, SE = 5.28), 
150 min (M = 29.46, SE = 7.99) or 180 min (M = 30.05, SE = 7.89). No other main or interaction 
effects were observed for the remaining items (all p’s > .05).  
 Tiffany-Drobes QSU-Brief. A significant condition x time interaction was observed for 
Factor 1 (intention to smoke; Figure 8). Post-hoc tests revealed that Factor 1 scores were lower at 
baseline (M = 11.09, SE = 2.02) than at 90 min (M = 20.18, SE = 2.16, p < .05), 120 min (M = 
21.64, SE = 2.18), 150 min (M = 21.91, SE = 2.35) and 180 min (M = 23.18, SE = 2.17, p’s < 
.01) in the abstinent condition, but not lower than 30 min (M = 14.82, SE = 2.32) or 60 min (M = 
17.36, SE = 2.36). No significant differences were observed between timepoints within the ad lib 
condition, or between conditions. For Factor 2 (anticipation of relief from withdrawal), 
significant main effects of condition and time were observed. Factor 2 scores were higher in the 
abstinent condition (M = 3.75, SE = 0.99) than in the ad lib condition (M = 2.65, SE = 0.70). 
Post-hoc tests were not reliable for the main effect of time for Factor 2.  
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 DENS. There was a significant condition x time interaction for weak (F = 3.22, p < .05; 
Figure 9), with ratings higher at baseline (M = 17.55, SE = 7.51) than at 60 min (M = 1.82, SE = 
0.92), 90 min (M = 0.91, SE = 0.32), 120 min (M = 1.00, SE = 0.38), 150 min (M = 1.09, SE = 
0.50), and 180 min (M = 0.91, SE = 0.55) in the abstinent condition (Tukey’s HSD, p’s < .05), 
but not 30 min (M = 9.36, SE = 5.26). There were no significant differences between ad lib and 
abstinent conditions at any timepoint. There were significant main effects of time for dizzy, heart 
pounding, and lightheaded (F’s > 4.45, p’s < 05); however, post-hoc tests did not demonstrate 
significant differences between any timepoints for these outcomes. For lightheaded for instance, 
the item with the larges F value for the main effect of time (F = 5.98), baseline values (M = 
34.46, SE = 10.60) were not significantly higher than at 30 min (M = 18.50, SE = 7.65), 60 min 
(M = 13.50, SE = 4.74), 90 min (M = 8.41, SE = 3.19), 120 min (M = 7.41, SE = 3.20), 150 min 
(M = 5.91, SE = 2.46), or 180 min (M = 6.77, SE = 2.77. There were no significant main effects 
or interactions for any of the other DENS items. 
 DEPS. Significant condition x time interactions were observed for the DEPS items of 
pleasant and satisfying (F’s > 3.61, p’s < .05). For pleasant, average ratings were 72.00 (SE = 
5.98) at baseline, 43.18 (SE = 11.72) at 30 min, 47.91 (SE = 13.51) at 60 min, 50.09 (SE = 14.11) 
at 90 min, 50.82 (SE = 14.46) at 120 min, 52.46 (SE = 14.65) at 150 min, and 54.18 (SE = 14.80) 
at 180 min in the abstinent condition (Figure 10). However, post-hoc tests revealed a significant 
difference between baseline and 30 min only (Tukey’s HSD, p < .05). No differences were 
observed between timepoints within the ad lib condition, and ratings were significantly higher at 
the 30-min timepoint for ad lib (M = 74.18, SE = 7.32) relative to abstinent conditions (Tukey’s 
HSD, p < .01). For satisfying, average ratings were 70.91 (SE = 5.96) at baseline, 44.00 (SE  = 
10.80) at 30 min, 46.64 (SE = 13.21) at 60 min, 49.27 (SE = 13.99) at 90 min, 50.27 (SE = 14.37) 
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at 120 min, 52.36 (SE = 14.31) at 150 min, and 52.35 (SE = 14.37) at 180 min in the abstinent 
condition. However, post-hoc tests revealed significant differences between baseline to 30 min 
and 60 min only (Tukey’s HSD, p < .05). No significant differences were observed between 
timepoints within the ad lib condition, and ratings were significantly higher at the 30-min 
timepoint for ad lib (M = 77.64, SE = 5.63) relative to abstinent conditions (Tukey’s HSD, p < 
.01). There was a significant main effect of time for calm, however, post-hoc tests were not 
reliable. There were no significant main effects or interactions for any of the other DEPS items.  
Randomization and Training 
Randomization to condition resulted in five participants receiving the ad lib session first 
and six participants receiving the abstinence condition first. Randomization was matched based 
on RVIP percent correct at screening, which was demonstrated to be successful: 54.60% (SE = 
6.48) versus 54.83% (SE = 7.98) for these groups, respectively, t(9) = -0.02, p = 0.98. During 
training, the number of practice tasks completed was 3 – 4 (M = 3.18, SD = 0.41) for the RVIP, 2 
– 3 (M = 2.45, SD = 0.52) for the n-back, and 1 - 2 (M = 1.09, SD = 0.30) for Cued Go/No-Go. 
Table 8 describes the best performance on cognitive tasks during training for all completers.  
Cognitive Tasks 
 Table 9 demonstrates t-test results for all cognitive outcomes. Table 10 shows mean 
cognitive task performance for both conditions at baseline and 120 min, and Table 11 shows 
means and standard deviations for change in cognitive performance from zero min to 120 min in 
each condition.  
 RVIP. As shown in Table 9, no RVIP-related outcomes showed significant differences 
between timepoints (all p’s > .05). Figure 11 demonstrates mean and standard error for percent 
correct for the ad lib and abstinent sessions at baseline and 120 min. 
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 N-back. A paired-samples t-test demonstrated significantly better 3-back accuracy at 120 
min abstinence (M = 69.00, SE = 6.49) than baseline abstinence (M = 51.09, SE = 5.95; FDR, p 
< .005; Figure 12). There were no other significant differences for any n-back outcomes (Table 
9). 
 Cued go/no-go. Incongruent accuracy was poorer in the abstinence condition at 120 min 
(M = 97.36, SE = 0.51) compared to baseline (M = 99.00, SE = 0.40), t(10) = -3.99, p = .003, d = 
1.08 (FDR, p < .005; Figure 13). Incongruent accuracy was also poorer at 120 min abstinence 
compared to 120 min ad lib use (M = 98.73, SE = 0.41), t(10) = -2.68, p = .023, d = 0.90, 
however, this finding did not remain significant after the FDR procedure for multiple 
comparisons. There were no other significant differences for any cued go/no-go outcomes (Table 
9). 
 Order effects. Cognitive tasks were investigated to determine if session order influenced 
cognitive performance. Though no inferential tests were run, Table 12 demonstrates means and 
standard deviations for all cognitive outcomes for both sessions and timepoints. Visual 
inspection of the means does not suggest any clear order effects across outcomes. 
Multiple Choice Procedure 
 Table 13 demonstrates crossover points for each session and timepoint. A paired samples 
t-test demonstrated a significantly higher crossover point at 150 min abstinence (M = 2.15, SE = 
0.50) compared to baseline abstinence (M = 1.51, SE = 0.40), t(10) = 2.38, p = .039, d = 0.42, 
however, this finding was not significant after the FDR procedure for multiple comparisons. 
There was not a significant difference in crossover point between 150 min abstinent and 150 min 
ad lib use, t(10) = 1.93, p = .083, d = 0.23.  
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Puff Topography 
 Interrater reliability coefficients were high for puff duration (ICC = 0.93, p < .001) and 
for IPI (ICC = 1.00, p < .001). Interrater agreement was high for puff number (kappa = 1.00, p = 
.001).  
Participants took an average of 51.44 puffs (SD = 20.93, Range = 17 – 77, Median = 58) 
in the 180-min ad lib session. Average puff durations for participants were 2.76 sec (SD = 1.24, 
Range = 1.13 – 4.58, Median = 2.53) with an average IPI of 239.23 sec (SD = 107.56, Range = 
137.41 – 468.83, Median = 184.54). Table 14 demonstrates the clustering patterns of each 
participant. This session consisted of 41.93% single puffs (SD = 27.73, Range = 0.00 – 88.24%, 
Median = 45.76%), for an average of 17.33 puffs for this puff type (SD = 9.71, Range = 0 – 28, 
Median = 19). For clustered puffs, 49.37% were deemed short (SD = 21.86, Range = 11.76 – 
76.92%, Median = 54.24%), 7.75% were deemed medium (SD = 12.00, Range = 0.00 – 29.87%, 
Median = 0.00%), and 0.0% were deemed large. The average number of puff clusters per session 
was 11.00 (SD = 6.67, Range = 1 – 21, Median = 12), with an average of 10.33 small clusters 
(SD = 6.46, Range = 1 – 21, Median = 12) and 0.67 medium clusters (SD = 1.12, Range = 0 – 3, 
Median = 0). All participants had at least 1 short puff cluster, though only three participants had 
a medium cluster. The average time between a cluster and the following puff was 356.46 sec (SD 
= 156.60, Range = 185.56 – 661.53, Median = 339.69), with an average of 1.70 puffs (SD = 1.16, 
Range = 0.2 – 3.2, Median = 1.56) between each cluster. In comparison, the average time 
between a single puff and the following puff was 338.91 sec (SD = 202.50, Range = 189.88 – 
819.00). There was an average of 2.71 puffs (SD = 0.61, Range = 2 – 3.85, Median = 2.44) 
within short clusters and an average of 6.56 puffs (SD = 0.96, Range = 6 – 7.67, Median – 6.00) 
within medium clusters.  
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Figures 14-16 demonstrate puffing patterns for three individual participants: 501, 507, 
and 513. These participants were chosen to represent of the wide variation in puffing patterns 
across participants. Participant 501 was an individual who took relatively many puffs in the ad 
lib condition (65), 95.38% of which were taken in clusters. Participant 507 was an individual 
who took relatively few puffs (17), and 88.24% of these puffs were single puffs. Participant 513 
was an individual who took a relatively moderate number of puffs in the ad lib condition (50), 
which were somewhat split between single (56.00%) and clustered puffs (44.00%). In addition to 
these puffing patterns, Figures 17-19 demonstrate puffs plotted with heart rate and ratings of 
urges from the MNWS. It is difficult to discern a clear pattern when viewing these graphs. For 
example, participant 501 takes few puffs and has a large increase in ratings of “urges” from 0 – 
30 minutes, but these ratings stay fairly stable after decreasing between 30 – 60 minutes 
regardless of puffing. Participant 507 reports having no urges to vape (i.e., rating of zero) at 30 
minutes despite taking no puffs since the standardized bout at the beginning of session, and their 
ratings seemingly increase when more puffs are taken (60 – 90 minutes) and decrease when 
fewer puffs are taken (120 – 150 minutes). The trends for participant 513 are even less clear, 
especially considering their ratings of “urges” stay stable across the session despite taking many 
puffs from 150 – 180 minutes. Generally, heart rate fluctuates for all participants but stays stable 
around a consistent mean. Taken together, these graphs suggest that there is a large amount of 
variability between- and within-participants in these outcomes, and differences may be difficult 
to detect without the use of statistical techniques.  
Predicting Withdrawal from Topography 
 Multiple linear regressions were conducted to determine if withdrawal and nicotine-
related outcomes could be predicted based on puff topography in the ad lib session. Total puff 
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number, average puff duration, average IPI, and the number of puff clusters were entered into the 
model as predictor variables. These variables were grouped into 30-minute bins (e.g., 0 – 30 
minutes, 30 – 60 minutes, 60 – 90 minutes, etc.) and paired with the outcome variable at the end 
of that time period (e.g. heart rate at 30 minutes, 60 minutes, 90 minutes, etc.). Multicollinearity 
was assessed due to the high correlation between puff number and the number puff clusters. VIF 
was 4.33 for puff number and 3.70 for puff clusters. It is difficult to determine if these values 
indicate problematic multicollinearity (one rule of thumb is VIF > 4), so significant models were 
rerun twice removing puff number or puff clusters from the models individually. Situations in 
which the model changed upon removing puff number of puff clusters are reported in text. 
However, due to the exploratory nature of these analyses, the full regression models for all 
outcomes are presented in Table 15.  
 Heart rate. Heart rate was predicted significantly based on topography variables (Table 
15). Specifically, longer puff durations and more puff clusters were associated with lower heart 
rate. Removal of puff clusters from the model led to the model no longer significantly predicting 
heart rate. However, the model remained significant when puff number was removed and longer 
puff durations again were associated with lower heart rate.  
 MNWS. Craving, drowsy, hunger, impatient, and irritable were significantly predicted by 
puff topography (Table 15). Notably, impatient had the largest variance accounted for (R2 = 
0.42) of all models. Longer puff durations were associated with increased ratings of craving, 
drowsy, hunger, impatient, irritable, as well as anxious and restless though those two full models 
were not significant. Longer IPIs were associated with increased ratings of craving and urges, 
though the full urges model was not significant. Longer IPIs were also associated with reduced 
ratings of drowsy. Increased puff number was associated with reduced ratings of irritable, and 
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more puff clusters were associated with increased ratings of hunger and irritable. Removal of 
puff number or puff clusters led to irritable no longer being significantly predicted by puff 
topography. For impatient and craving, removing puff clusters led to higher puff numbers being 
associated with higher ratings. All other models remained significant when puff number or puff 
clusters were removed from the model. Models for other MNWS were not significantly predicted 
by puff topography variables.   
 Tiffany-Drobes QSU-Brief. Neither Factor 1 nor Factor 2 were predicted significantly 
by puff topography (Table 15), though longer puff durations were associated with higher ratings 
of Factor 2.  
 DENS. Ratings of nervous and excessive salivation were significantly predicted by 
topography variables (Table 15). Increased puff number was associated with lower ratings of 
nervous and more puff clusters were associated with increased ratings of nervous and excessive 
salivation. The nervous model was no longer significant when puff number was removed, and 
the nervous and salivation models were no longer significant when puff clusters were removed. 
No other DENS models were predicted significantly by puff topography, though more puff 
clusters were associated with increased ratings of confused. 
 DEPS. Ratings of awake, concentrate, pleasant, reduced hunger, satisfying, and taste 
good were significantly predicted by puff topography. However, no individual puff topography 
variables predicted awake, pleasant, satisfying, or taste good. Shorter puff durations were 
associated with higher ratings of concentrate and reduced hunger, and shorter IPIs were 
associated with higher ratings of reduced hunger. For satisfying, pleasant, and taste good, 
removal of puff clusters led to a positive association between puff number and these items, and 
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removal of puff number led to a positive association between puff clusters and the items. No 
other DEPS items were predicted significantly by puff topography.  
Chapter 4 - Discussion 
Overview of Study Aims 
This study is the first to assess short-term withdrawal in experienced ECIG users that are 
primarily nonsmokers. That is, previous work assessing withdrawal has included ECIG users 
who are current or former cigarette smokers (Dawkins & Corcoran, 2014; Hughes et al., 2019a), 
thus presenting a confound. In this study, withdrawal was assessed using a within-subjects 
design in which participants abstained from ECIG use or used their own ECIG ad lib for 180 
min. Primary aims were to: a) assess feasibility of the current study; b) determine characteristics 
that predict ECIG dependence; and c) assess the effects of 180 min of abstinence versus 180 
min of ad lib ECIG use on heart rate and subjective withdrawal and nicotine effects. Secondary 
aims were to: a) assess the effects of abstinence and ad lib ECIG use on measures of cognition 
and ECIG reward; b) characterize puff topography during 180 min of ad lib ECIG use; and c) 
explore if puff topography variables are predictive of withdrawal and nicotine effects 
experienced during ad lib ECIG use.  
Feasibility and Recruitment 
  The number of individuals determined to be eligible among those who completed the 
telephone screening questionnaire was low (23.03%). A primary reason for ineligibility was 
relatively low scores on the PSECDI (< 7), with 18.3% of callers being excluded for this reason 
alone and 41.6% of callers being excluded for this and other reasons. While this criterion was 
chosen in an effort to exclude those individuals least likely to be ECIG dependent, the PSECDI 
scale has not been validated. Perhaps telling is that, for those who completed the study, a lower 
ACUTE ABSTINENCE EFFECTS OF ECIG USERS 54 
proportion were deemed “highly” dependent using the PSECDI than using the MINI for Tobacco 
Use Disorder (i.e., 36.4% vs 63.6%, respectively). Another common reason for ineligibility was 
marijuana use (32.12%), but the use of this criterion is important given the potential effects of 
acute or chronic marijuana use on cognitive functioning (for review, see Crean, Crane, & Mason, 
2011). Many participants also were excluded due to their past year and/or past month cigarette 
use (32.12%). This proportion of ECIG users with relatively little cigarette smoking history is 
comparable to that reported in recent samples of young adults (69% - 78.4% for college students, 
Ickes et al., 2019; Leavens et al., 2019;), the age range for the majority of those screened and 
completed here. This pattern is further supported by recent work with college-aged Juul users, of 
which only 4.1% reported former cigarette smoking (Leavens et al., 2019). Interestingly, eligible 
and ineligible participants did not differ on most baseline characteristics related to cigarette and 
ECIG use history. Besides a higher PSECDI score and lower rates of cigarette use, eligible 
participants differed from ineligible participants only in that they reported more days/week of 
ECIG use. 
Another hindrance to enrollment rates involved the high proportion of eligible callers 
who failed to respond to requests to schedule an in-person screening visit (46.34%). These 
individuals may have decided that they were not interested in participation, or may not have been 
responsive to our methods of communication. Early in the study, we relied on the use of 
telephone-based correspondence; however, use of digital technology such as texting, e-mail, and 
online screening questionnaires have been argued as more acceptable communication methods 
among younger generations (Dalessandro, 2018; Haste, 2005). While we did not target this 
younger age group for participation, they appear to be those most likely to fit our criteria. 
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Consequently, email and text messaging forms of communication were later offered as an option 
to individuals interested in participation. 
 Of those who appeared eligible based on the telephone screen (n = 41), twenty-two 
(53.7%) showed for the in-person screening and were therefore consented for the study. 
However, seven (31.82%) of these individuals were ultimately deemed ineligible based on the 
in-person screening procedures and did not begin the study. The primary reason for ineligibility 
at this stage was individuals’ discrepant responses between the telephone phone screening and 
in-person screening questionnaires. For the 15 participants that began the study, 11 (73.33%) 
completed both sessions. For most individuals who failed to attend scheduled screening (37.1%) 
or session (40.5%) appointments, reasons for nonattendance were generally unknown. 
Unfortunately, the published literature rarely details eligibility or enrollment rates, as well as 
reasons for dropout or non-attendance (e.g., Dawkins, Turner, Hasna, & Soar, 2012; Hendricks et 
al., 2006; Parrott et al., 1996; Wesnes et al., 2013), making it difficult to determine if these rates 
are unique to the current study.  
 Some of the encountered difficulties may be a result of the young adult, college student 
sample (63.6% college students) that participated in the study (for review, see Khatamian Far, 
2018). Characteristics of young adult populations include poor impulse regulation, delay of 
gratification, and vulnerability to peer influence (Steinberg, 2007), which may be barriers to 
regular participation in a research study. College students self-report scheduling conflicts and 
lack of time as logistical conflicts to participation (Davidson et al., 2010; Khatamian Far, 2018). 
These issues may be particularly relevant for the current study, in which experimental sessions 
required participants to have at least 3.5 hours of uninterrupted time. In the current study, 57.1% 
of college students took longer than 2 weeks to complete the study (median = 16 days), as 
ACUTE ABSTINENCE EFFECTS OF ECIG USERS 56 
compared to only 25% of non-students (median = 8 days). However, attempts to recruit non-
college community members via advertisements (e.g., fliers in vape shops) and online postings 
(Facebook vaping groups, Craigslist) were not highly successful and received lower response 
rates over time. Additionally, the recruitment strategies used for this study included those passive 
(fliers, emails) and active (attending classes, information booths), as recommended by others 
(Khatamian Far, 2018).  
Predictors of ECIG Dependence 
To evaluate the predictors of nicotine dependence, a convenience sample was used. Of 
the 178 individuals included in this sample, the large majority were college students and thus of 
relatively young age. Fourth generation pod systems were commonly used, such as Juul (similar 
to Ickes et al., 2019; Leavens et al., 2019). Not surprisingly, therefore, the average liquid nicotine 
concentration was high and the average power output was low. Also, the preferred liquid flavors 
were mint and fruit, which are the first and second most common flavors among college students 
who use Juul (Leavens et al., 2019), and the third and fourth most common flavors among adult 
ECIG users (Yingst, Veldheer, Hammett, Hrabovsky, & Foulds, 2017). Approximately one-third 
of the sample reported smoking more than 100 cigarettes in their lifetime, though the majority of 
this subsample reported relatively low levels of cigarette use in the past month (e.g., 60.47% 
reported 0 cigarettes; 86.05% reported < 10 cigarettes) and year (e.g., 31.42% reported 0 
cigarettes; 51.42% reported < 10 cigarettes). The average PSECDI scores of this sample 
indicated moderate levels of ECIG dependence, equivalent to average PSECDI scores reported 
previously for a large sample of current ECIG users who were former cigarette smokers (8.53 
versus 8.1, respectively; Foulds et al., 2015). Similar, or slightly higher scores, have been 
reported elsewhere (e.g., ~8-12; Hiler et al., 2017; Hu et al., 2019; Leavens et al., 2019; Spindle 
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et al., 2018) among experienced ECIG users, though these scores indicate low to moderate 
dependence and are notably low on a scale with a maximum score of 20 (Foulds et al., 2015). 
The best model to predict ECIG dependence was that which included all predictors. In 
this model, older participants, higher nicotine concentrations, daily ECIG use, longer durations 
of use, and higher device wattages predicted higher ECIG dependence scores, though smoking 
status and volume of liquid/day did not. This pattern is consistent with previous work 
documenting positive associations between these same variables and ECIG dependence scores as 
measured by PSECDI (Foulds et al., 2015; Piper, Baker, Benowitz, Smith, & Jorenby, 2019) or 
other measures (Johnson et al., 2018; Morean et al., 2018; Piper et al., 2019). Higher PSECDI 
scores have also been associated with the use of more advanced generation ECIGs (i.e., 2nd and 
maybe 3rd generation devices; Foulds et al., 2015; Yingst et al., 2015), and these devices 
typically have higher wattages. Higher wattages (Kosmider, Spindle et al., 2018) and higher 
nicotine concentrations (Hiler et al., 2017; Ramôa et al., 2016) are associated with increased 
nicotine delivery, which may promote greater dependence. No relationship was found between 
cigarette smoking and ECIG dependence, a finding supported by some work (Johnson et al., 
2018) but not others (Morean et al., 2019). Daily volume of liquid used also was not a significant 
predictor (similar to Browne & Todd, 2018), though ECIG consumption patterns are difficult to 
characterize (Blank et al., 2016; Pearson et al., 2018). Depending on the type of device used, 
individuals may rely on a myriad of behaviors to estimate their daily consumption: number of 
single puffs, number of clustered puffs, number of pods/cartridges/tanks, ml of liquid, etc. (Blank 
et al., 2016). For obvious reasons, some of these behaviors may be easier to estimate than others, 
and users may ultimately be inaccurate in their reporting. In support of this idea, the correlation 
between liquid consumption and the reported number of ECIG uses/day was notably low in the 
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current study. For example, one caller reported using 32 ml/day in 15-19 ECIG uses (15 puffs or 
10 minutes of use), while another caller reported using 0.1 ml/day in 30+ daily ECIG uses.   
 These results should be interpreted with caution, as the full model only accounted for 
18% of the variance in dependence scores. Also concerning is that the predictor variables 
revealed low correlations with the PSECDI scores, and were not normally distributed even after 
their transformation. Additionally, higher nicotine concentrations are used with lower wattages 
(Browne & Todd, 2018; Smets et al., 2019) and were strongly negatively correlated in the 
current sample, which may have caused multicollinearity issues that impacted beta weights and 
inflated standard errors for those predictors. Daily ECIG use and use duration may have the most 
reliable relationships with ECIG dependence, as these predictors remained significant as 
nonsignificant predictors were removed. Though interaction variables were not used in these 
regressions due to violations of assumptions and unclear utility, it would benefit the field to 
continue to develop mathematical models regarding the interaction of device features and puff 
topography to predict nicotine yield (Hensel et al., 2019; Talih et al., 2015; Talih et al., 2017) 
and delivery. Continued assessment of ECIG characteristics, use behavior, and dependence will 
provide a comprehensive understanding of which factors of ECIG use are encouraging 
dependence among users.  
Abstinence Effects on Primary and Secondary Outcomes 
 Another goal of this work was to compare subjective, physiological, cognitive, and 
behavioral outcomes between acute periods of ECIG abstinence and ad lib use. These analyses 
were conducted for those eleven participants who completed the entire study. Completers were 
primarily young adult nonsmokers (90.9%) who used 4th generation pods (72.7%) with high 
average nicotine concentrations, and had a preference for mint (45.5%) and fruit (45.5%) flavors. 
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They also had been using ECIGs daily for nearly two years on average, and had moderate-high 
levels of ECIG dependence.  
Heart rate. For heart rate, significant increases were observed from pre- to post-directed 
bout in both conditions, suggesting that users were exposed to nicotine at the onset of sessions 
(similar to Hiler et al., 2017; Spindle et al., 2017; Spindle et al., 2018). Heart rate decreased 
thereafter for both conditions when examined across time, though to a greater degree for ECIG 
abstinence than for ad lib. Consequently, average heart rate was significantly lower for ECIG 
abstinence, when values were collapsed across time. A similar pattern of results has been 
observed in cigarette smokers undergoing a brief period of abstinence (Hendricks et al., 2006; 
Parrott et al., 1996). This effect may be a physiological indicator of nicotine withdrawal (Ward, 
Garvey, & Bliss, 1992) or a nicotine offset effect (Shiffman, West, & Gilbert, 2004; West & 
Schneider, 1988). Offset effects are observed upon immediate removal of the drug, such as that 
experienced when an ECIG user stops puffing on their device. An example might be when heart 
rate declines because it is no longer increasing from the nicotine absorbed during ECIG puffing. 
These declines in heart rate may remain stable over a long period (e.g., 5 weeks in West & 
Schneider, 1988), which may reflect a lack of nicotine rather than a temporary withdrawal effect.  
 Subjective effects. As for subjective effects, significant interactions between condition 
and time occurred for several items known to be reliable indicators of nicotine/tobacco 
withdrawal, specifically craving, urges to vape, and Factor 1 (intention to vape). For each of 
these items, significantly increased ratings were observed within 90 - 120 min after baseline for 
the abstinence but not the ad lib condition. Still, post-hoc tests failed to detect differences 
between timepoints when compared across conditions. A similar pattern was observed for some 
product-related effects (i.e., satisfying and pleasant), though ratings found to be significantly 
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different from baseline were those earlier in the session (e.g., 30-60 min). Also observed were 
significantly higher ratings for Factor 2 (anticipation of relief from withdrawal) for the 
abstinence relative to ad lib condition (collapsed across timepoints), as well as lower ratings of 
various withdrawal- and product-related items (e.g., difficult concentrating, impatient, irritable, 
lightheaded, dizzy) at baseline relative to other timepoints (collapsed across conditions). For 
these latter effects, however, differences between timepoints were not significant based on post-
hoc tests. Cigarette smokers have shown similar changes in withdrawal symptoms as early as 30 
min (e.g., craving, anxiety, difficulty concentrating; Hendricks et al., 2006), and as late as four 
hours (e.g., urges to smoke, irritability, difficulty concentrating; Parrott et al., 1996), during an 
acute period of abstinence. Importantly, the magnitude of ratings reported here is similar to that 
reported by Hendricks and colleagues (2006), as well as in other work that assessed withdrawal 
in experienced ECIG users following a period of overnight abstinence (Hiler et al., 2017; Spindle 
et al., 2017; Spindle et al., 2018). 
 A recently published study (Hughes et al 2019b) assessed longer-term ECIG withdrawal 
in a sample of experienced users with minimal cigarette smoking history (< 100 cigarette uses in 
lifetime). Participants used their own ECIG device as usual for one week or no ECIG device for 
one week, and thus experienced a period of ad lib use and a period of abstinence. Withdrawal 
effects and heart rate were measured during these two weeks. Relative to the period of regular 
ECIG use, the abstinence period resulted in reduced heart rate and elevated withdrawal ratings. 
These effects peaked within the first two days of abstinence, and were most pronounced for the 
subjective items of craving and irritability. When making comparisons across studies, however, 
the withdrawal symptoms observed among this sample of non-smoking ECIG users appears 
reduced relative to ECIG users that are former smokers (Hughes et al., 2019a). This observation 
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has led to the suggestion that ECIG withdrawal in non-smokers may not be of clinical or 
regulatory significance (Hughes et al., 2019a). 
In a national dataset, 25% of exclusive ECIG users met the DSM-5 definition of 
withdrawal (experience 4+ withdrawal symptoms) when trying to quit, and only 40% of users 
experienced at least one withdrawal symptom (Hughes & Callas, 2019). Less withdrawal 
symptoms were experienced by ECIG users trying to quit than cigarette smokers, however, not 
all ECIG users were daily users. Anger, anxiety, and eating more were the most common 
withdrawal effects reported, though many of the effects reported in the current study (craving, 
urges, impatient), were not assessed. Notably, this study involved a small sample of ECIG users 
(n = 25) and their history of cigarette use is unknown. It remains unclear if other measures of 
withdrawal (e.g., difficulty concentrating, restlessness) are not experienced by ECIG users as 
severely as cigarette smokers or if longer abstinence periods are needed for ECIG users to 
demonstrate these withdrawal effects. Future studies with a longer abstinence duration and a 
larger sample will provide additional insight into the primary symptoms and timecourse of ECIG 
withdrawal.  
 Cognitive effects. Given the low sample size, and thus the lack of statistical power, few 
significant effects were observed for the cognitive measures. Indeed, neither significant 
condition nor time effects were detected for any RVIP outcome. For cigarette smokers, deficits 
in RVIP reaction time have been observed by 30 min of abstinence (Hendricks et al., 2006) and 
RVIP accuracy after overnight abstinence (McClernon et al., 2008; Parrott & Craig, 1992; 
Wesnes & Warburton, 1984). Attention as measured by other tasks have also been sensitive to 
cigarette abstinence-induced changes in reaction time or accuracy within two to six hours 
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(Parrott et al., 1996), 12 hours (Leventhal et al., 2010; McClernon et al., 2008; Myers et al., 
2008; Parrott & Craig, 1992), and 17 hours (Atzori et al., 2008).  
For inhibitory control, No-Go Incongruent accuracy was decreased significantly at the 
end of the abstinence condition (120 min), relative to baseline for abstinence and also relative to 
the end of the ad lib condition (120 min). No-Go Incongruent trials may be a particularly robust 
measure of inhibitory control, as errors of commission for No-Go trials have shown to increase 
in cigarette smokers after 24 hours of abstinence (Hatsukami et al., 1989; Kozink, Kollins et al., 
2010). Also shown in cigarette smokers are deficits in reaction times on this same task within 5 
hours (Harrison et al., 2019) and 8-12 hours (McClernon et al., 2008) of abstinence. In this study, 
reaction time was not influenced by condition or time. 
 The only significant finding for the n-back task was a significant difference between 
timepoints within the abstinence condition for 3-back accuracy. Specifically, accuracy was 
significantly higher at 120 min compared to baseline for this condition. A similar pattern was 
observed for the ad lib condition, though the finding was not significant. It is possible that 
participants improved with repeated administrations of the 3-back task, or that the 3-back version 
administered at 120 min was easier than the version administered at baseline. In comparison, 
cigarette smokers reliably demonstrate deficits in working memory accuracy and reaction time at 
6 hours (Grundey et al., 2015), 12- 13 hours (Mendrek et al., 2006; Myers et al., 2008), and 24 
hours of abstinence (Falcone et al., 2014; Jacobsen et al., 2005). 
Study results for cognitive outcomes are not likely due to condition order, as 
randomization based on RVIP performance at screening was successful. Still, more extensive 
training might be warranted. Studies involving cognitive assessments have used different training 
procedures, such as training to stability or a specific criterion (Ernst et al., 2001; Kozink, Lutz et 
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al., 2010; Mendrek et al., 2006), multiple training sessions (Gilbert et al., 2005; Kozink, Lutz et 
al., 2010; Parrott et al., 1996; Wesnes & Warburton, 1984), or practice on the same day of the 
session (Harrison et al., 2009; Hendricks et al., 2006). The training session used in this study was 
similar to a single, 2.5 hour session used in other research (McClernon et al., 2008), though it is 
plausible that using more training sessions, training to a criterion, or training temporally closer to 
study sessions may have influenced outcomes. However, it is unclear how the style, duration, 
and timing of trainings may affect study results. Alternatively, ECIG withdrawal as characterized 
by cognitive deficits might require a longer period of abstinence. A larger sample size will be 
needed to determine whether the lack of findings is potentially due to these procedural 
limitations rather than low statistical power.  
ECIG reward. The MCP was used to assess the reward value of ECIGs among this 
sample of users. The crossover point at which participants chose 10 ECIG puffs over more 
money was significantly higher at 150 min compared to baseline within the abstinence condition. 
This same crossover point at 150 min for abstinence was also higher than at 150 min for ad lib 
use, though the difference was not significant. Studies that have used the MCP to evaluate ECIG 
reward have primarily done so in cigarette smokers (Maloney et al., 2019; McPherson et al., 
2016; Vansickel et al., 2012), or to assess the abuse liability of different ECIG devices in 
experienced users (Breland et al., 2019). Additionally, purchase tasks for ECIGs may be 
complicated given that ECIG users often do not quantify use in terms of puffs, and users of 
different ECIGS may quantify units differently (e.g., cartridges vs. ml of liquid; Cassidy, Tidey, 
Colby, Long, & Higgins, 2017). Thus, there is limited research for comparison to findings of the 
current study. In cigarette smokers, the reward value of cigarettes after overnight abstinence 
versus no abstinence has been demonstrated using a monetary choice paradigm (Betts & Tiffany, 
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2019) and a variable ratio schedule (Perkins et al., 1994). Results of this study suggest that the 
MCP may be a useful measure of to evaluate abstinence-induced changes in ECIG reward in 
future work.  
Puff Topography During 180 Minutes of ad lib ECIG Use 
 Interrater reliability was high for puff number, puff duration, and IPI, similar to that 
reported in our previous work that involved video-based measurement of ECIG puff topography 
during ad lib bouts (Felicione et al., 2019). While others have used video-based measurement 
and similar operational definitions for topography variables, they have not reported on the 
reliability and/or validity of this measurement method (Farsalinos et al., 2013a; St. Helen et al., 
2016). Puff durations observed in this study (2.8 sec) were higher than (1.8 sec; Lee, 
Nonnemaker, Bradfield, Hensel, & Robinson, 2018), lower than (3.5 – 5.9 sec; Farsalinos et al., 
2013a; Hiler et al., 2017; Ramôa et al., 2016; Robinson, Hensel, Morabito, & Roundtree, 2015; 
Spindle et al., 2017; St. Helen et al., 2016), or similar to (3.0 sec; Kosmider, Jackson, Leigh, 
O’Connor, & Goniewicz, 2018) observations reported previously. Differences across studies 
may be due to differences in the method of measurement used, such as computerized devices in 
the laboratory (3.5 – 5.9 sec; Hiler et al., 2017; Ramôa et al., 2016; Spindle et al., 2017), 
computerized devices out of the laboratory (1.8 – 3.5 sec; Kosmider, Jackson, et al., 2018; Lee, 
Nonnemaker et al., 2018; Robinson et al., 2015), or video recording of natural puffing in the lab 
(3.5 - 4.2 sec; Farsalinos et al., 2013a; St. Helen et al., 2016). They may also be due to 
differences in the type of ECIG device used: 1st (1.8 – 3.5 sec; Lee, Nonnemaker et al., 2018; 
Robinson et al., 2015;), and 2nd and/or 3rd (3.5 – 5.9 sec; Hiler et al., 2017; Ramôa et al., 2016; St 
Helen et al., 2016; Spindle et al., 2017). In the current study that allowed for natural puffing with 
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video-based measurement, the majority of participants used a 4th generation pod style device. No 
published studies to date have characterized puff topography among users of pod-style ECIGs.  
 The current study also sought to model the work by St. Helen and colleagues (2016) to 
characterize clusters of ECIG puffs. This approach may contribute to a determination of 
definitions for an ECIG-use bout because little is known about how participants puff over long 
ad lib periods or in their natural environment. Participants in the current study and St. Helen et 
al. (2016) had different clustering patterns, particularly when considering the percent of total 
puffs in a session. Participants in the current study had a notably larger percentage of single puffs 
in the session than participants in the St. Helen study (41.9% vs 11.9%, respectively), though the 
percentage of small puff clusters was similar across the studies (49.4% current study vs 42.9% 
St. Helen study). Differences also were observed between studies for medium clusters (7.8% vs 
27.8%) and large clusters (0% vs 16.5%). Despite these differences, the average number of puffs 
within small and medium clusters was comparable between studies. Additional puff topography 
differences were found for puff number: 64 puffs in a 90-minutes ad lib session (St Helen et al.) 
versus 51.4 puffs in 180 minutes in the current study. The longer ad lib session may better 
represent natural behavior, as an observational study found ECIG users took 156 puffs/day 
(Kosmider, Jackson et al., 2018). As mentioned earlier, puff durations were shorter in the current 
study than in the St. Helen study (2.8 sec vs. 3.5 sec), and IPIs in the current study were 
approximately double that of the St. Helen study (239.2 sec vs. 118 sec). The current study added 
novel data to the literature regarding the average IPI between the end of a cluster and the 
following puff (356.4 sec) and the average number puffs between clusters (1.7).  
 Study differences may account for differences in puff topography. Participants in St. 
Helen et al. (2016) used older ECIG types (tanks vs. pods), lower nicotine concentrations (8.4 
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mg/ml vs. 42.3 mg/ml) and were older (38.4 years vs. 20.6 years). Vaping sessions in the St. 
Helen study were shorter (90 min vs 180 min), required a pre-session abstinence period (4 hours 
vs. no requirement), and did not include administration of tasks or questionnaires, as opposed to 
multiple subjective and cognitive assessments in the current study. It is not surprising that 
differences in puff topography were observed between studies given the differences in 
participant characteristics and study design. However, alternate definitions of puff clustering 
may be worth consideration in future research, such as IPI length or the amount of puffs in small, 
medium, and large clusters. Observational studies have made participants define sessions by 
turning a topography measurement device on and off (Kosmider, Jackson, et al., 2018; Lee, 
Nonnemaker et al., 2018), and found that ECIG users took 10 – 12 puffs/session with an IPI of 
21.7 sec, though the amount of sessions differed between studies (3.5 – 15.3). This may suggest 
that how participants cluster puffs outside of the laboratory may differ from clustering in 
laboratory ad lib sessions, however, these studies involved the use of computerized topography 
devices that may influence puffing patterns (e.g., more sessions, no individual puffs). Continued 
research to define ECIG bouts can greatly benefit characterization of ECIG puff topography.  
 Individual differences should be considered when assessing ECIG puff topography. 
Large variability in puffing patterns can be observed in Figures 14 - 16, in which participant 501 
had almost all puffs in clusters (95.4%), participant 507 had few clustered puffs (11.8%) and 
participant 513 had a moderate amount of clustered puffs (44.0%). Similarly, large variability in 
the percentage of single puffs in a session was observed in the current study (0.0 – 88.2%) and 
by St. Helen et al. (0.0 – 42.3%). Wide ranges were also observed for puff number (17 – 77), 
average puff duration (1.1 s – 4.6 sec) and average IPI (137.4 s – 468.8 sec). Some previous 
research has characterized puff topography with an emphasis on individual subjects due to 
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differences in ECIG puffing patterns (Robinson et al., 2015; Robinson et al., 2016; St. Helen et 
al., 2016), and has split participants into groups based on puffing patterns (Robinson et al., 2015) 
or defined different types of vaping sessions (Lee, Morgan-Lopez et al., 2018). It likely will be 
useful to acknowledge different puffing patterns among ECIG users as researchers characterize 
ECIG bouts, as a standard definition may not be applicable to all ECIG users. 
Predicting Withdrawal from Puff Topography 
An exploratory outcome of the study was the prediction of withdrawal based on puffing 
topography. Topography significantly predicted 38.5% of subjective withdrawal outcomes and 
42.1% of nicotine/product effects. It was hypothesized that more puffs and  longer durations, 
would be associated with withdrawal, though the opposite pattern was found. For example, 
longer puff durations and fewer puff clusters were associated with reduced heart rate. Longer 
puff durations were commonly associated with higher ratings of subjective withdrawal (e.g., 
craving, hunger, impatient) and lower product effects (e.g., concentrate, reduce hunger). The 
strongest predictive effects were found for impatient, in which puff topography accounted for 
42% of the variance. However, the majority of these regressions accounted for less than 20% of 
the outcome variance, giving these analyses limited predictive validity.  
Results of these models are complicated to interpret due to third variables that may influence 
findings. Those that were more dependent may have used ECIGs more intensively and also 
experienced more severe withdrawal outcomes. An additional concern is the lack of control in 
long ad lib vaping sessions that may introduce other factors (e.g., boredom, cues) that can 
influence behavior and withdrawal. Similarly, ad lib vaping allows all vaping parameters (puff 
number, duration, IPI) to vary, as opposed to standardized puffing bouts that hold certain 
variables constant while others vary. These analyses would benefit from the use of a 
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computerized topography measurement device that can capture variables such as puff volume 
and flow rate. Finally, puff number and puff clusters were correlated, which potentially 
introduced issues of multicollinearity into regressions. 
Conclusions 
 There are several notable strengths of the current study. The use of an abstinence 
manipulation allows for the comparison between ad lib vaping and vaping abstinence, along with 
comparisons between baseline abstinence and increasing durations of abstinence. Including 
predeprived and nondeprived assessments gives strength to conclusions about abstinence-
induced deficits, rather than nicotine enhancement of performance (Heishman et al., 1994). 
However, future research with a non-smoking control group would allow for more definitive 
conclusions on this matter. Future research may also wish to include a 0 mg/ml nicotine 
condition (placebo-control), though the exclusion of this condition strengthens the ecological 
validity of the current study. The exclusion of regular cigarette smokers allows for conclusions 
regarding dependence and withdrawal in ECIG users that are not currently or formerly dependent 
upon cigarettes. The use of participants’ usual ECIGs in the ad lib condition created a more 
naturalistic representation of normal behavior than a standardized ECIG. Use of a participants’ 
usual ECIGs likely allows participants to puff more naturally and experience typical levels of 
nicotine exposure, which can have important implications for cognitive and subjective 
assessments. The current study includes measurement techniques and analyses that have been 
common in the cigarette dependence and withdrawal literature, but not ECIG literature. For 
example, little is known about cognitive performance in ECIG users under abstinent or ad lib 
conditions. Additionally, little work has been done to assess diagnoses of tobacco use disorder in 
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ECIG users, and few studies have assessed puff topography during long ad lib use bouts without 
a computerized topography device.  
 Future research should expand upon findings of the current study. The current study 
included a small sample size and was underpowered to detect small to moderate effect sizes. 
Increasing the sample size would provide important information regarding which effects exist 
but were underpowered in the current study versus which withdrawal symptoms may not be 
experienced by ECIG users. Additionally, the current sample may have limited generalizability 
to a larger population of ECIG users. Though ECIG use among nonsmokers is highest in young 
adults (Schoenborn & Gindi, 2016), adolescent and older adult ECIG users may differ in use 
patterns and dependence from young adult users. Similarly, most participants in the current 
sample used 4th generation pod devices. These devices may have nicotine delivery profiles 
different from that of other ECIGs, which may influence withdrawal and puff topography. The 
current study also sought out individuals with higher ECIG dependence scores, and thus these 
participants may have experienced greater withdrawal than the average ECIG user. A longer 
abstinence manipulation would help further characterize the timecourse of ECIG withdrawal and 
determine if certain effects, particularly cognitive effects, are experienced later than two hours of 
abstinence. While studies of cigarette smokers have shown abstinence-induced effects within two 
hours (Hendricks et al., 2006; Parrott & Craig, 1996), other studies have shown less reliable 
effects at early hours of abstinence (Hatsukami et al., 1989; Heimstra, Fallesen, Kinsley, & 
Warner, 1980). Assessing the effects of overnight abstinence on cognitive performance is an 
essential next step for characterizing ECIG withdrawal. Currently, the only method to verify 
short-term ECIG abstinence is to test plasma nicotine concentrations or observe users in the lab. 
Testing plasma nicotine concentrations is not always feasible, making alternate biochemical tests 
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of ECIG abstinence of great utility to researchers. An inpatient study in which ECIG users are 
held overnight to confirm abstinence would help define the effects of a longer abstinence 
duration until such tests are available. Additional future directions may involve the comparison 
of ECIG users of different device types. The type of ECIG used likely influences puff 
topography, nicotine delivery (Wagener et al., 2017), and may affect subjective responses and 
cognitive performance. While the current study involved mostly 4th generation pod users and 
some 3rd generation mod users, the sample size was not large enough to characterize differences 
between these groups. Additional considerations may include widening inclusion criteria to 
include participants that score lower on ECIG dependence. As mentioned previously, the current 
study purposely sought out those higher in ECIG dependence, and thus, the findings likely are 
not generalizable to a larger population of ECIG users.  
Despite the limitations, the current study is novel in that it a) assessed the effects of short-
term abstinence on ECIG withdrawal symptoms and b) assessed puff topography, subjective 
reports, cognitive performance, ECIG reward, and dependence measures in ECIG users that are 
not cigarette smokers. Generally, increases in subjective withdrawal symptoms and reductions in 
heart rate and nicotine effects were observed in the abstinence condition, with onset of effects 
within two hours of abstinence. Mixed results were observed for cognitive tasks, with the 
clearest abstinence-induced deficits observed for response inhibition. Findings of the study must 
be interpreted with consideration to limited power and generalizability; however, it provides 
evidence of the early onset of ECIG withdrawal, indicates that non-smoking ECIG users are 
nicotine dependent, and sets a foundation for research to continue studying these effects in the 
future.  
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Table 1 












1. Tobacco is often taken in larger amounts or over a longer period than was intended.
2. There is a persitent desire or unsuccessful efforts to cut down or control tobacco use.
3. A great deal of time is spent in activities necessary to obtain or use tobacco.
4. Craving, or a strong desire or urge to use tobacco
7. Important social, occupational, or recreational activities are given up or reduced because of tobacco use.
8. Recurrent tobacco use in situations in which it is physically hazardous (e.g., smoking in bed)
10. Tolerance, as defined by either of the following:
11. Withdrawal, as manifested by either of the following:
       a. The characteristic withdrawal syndrome for tobacco use .
       b. Tobacco (or a closely related substance, such as nicotine) is taken to relieve or avoid withdrawal  
       symptoms.
       a. A need for markedly increased amounts of tobacco to achieve the desired effect.
       b. A markedly diminished effect with continued use of the same amount of tobacco.
A. A problematic pattern of tobacco use leading to clinically significant impairement or distress, as manifested by 
at least two of the following, occuring within a 12-month period
6. Continued tobacco use despite having persistent or recurrent social or interpersonal problems caused or 
exacerbated by the effects of tobacco (e.g., arguments with others about tobacco use)
5. Recurrent tobacco use resulting in a failure to fulfill major role obligations at work, school, or home (e.g., 
interference with work)
9. Tobacco use is continued despite knowledge of having a persistent or recurent physical or psychological 
problem that is likely to have been caused by tobacco.
ACUTE ABSTINENCE EFFECTS OF ECIG USERS 98 
Table 2 















Table 2. Diagnostic Criteria for Tobacco Withdawal
A. Daily use of tobacco for at least several weeks.







B. Abrupt cessation of tobacco use, or reduction in the amount of tobacco used, followed within 24 hours by 
four (or more) of the following signs or symptoms:
C. The signs or symptoms in Criterion B cause clinically significant distress or impairement in social, 
occupational, or other important areas of functioning.
D. The signs or symptoms are not attributed to another medical condition and are not better explained by 
another mental disorder, including intoxication or withdrawal from another substance.
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Table 3 
Mean (SD) or percentage for demographic, cigarette use, and ECIG use characteristics of all 








All callers Ineligible Eligible Completers
n = 178 n = 137 n = 41 n = 11
Age 20.96 (4.14) 20.89 (4.21) 21.20 (3.92) 20.63 (2.06)
% Smokers (> 100 cigarettes lifetime) 27.40% 31.62% 12.50% 9.10%
Lifetime 9633.33 (30397.90) 9933.33 (32300.10) 4660 (9701.19) 100.00 (n/a)
Past year 206.55 (1041.00) 235.92 (1128.42) 0.20 (0.45) 1.00 (n/a)
Past month 4.80 (13.13) 5.34 (13.79) 0.00 (0.00) 0.00 (n/a)
% Nonmokers (< 100 cigarettes lifetime) 72.60% 68.38% 87.50% 90.90%
Mean (SD) Lifetime 14.45 (20.73) 14.55 (20.76) 13.74 (20.78) 8.80 (10.85)
Mean (SD) Past Year 4.15 (9.07) 5.07 (10.31) 1.84 (4.14) 6.50 (9.73)
Mean (SD) Past Month 0.45 (1.34) 0.62 (1.53) 0.00 (0.00) 2.33 (3.46)
ECIG Device Type
Pods (4th gen) 76.69% 79.67% 67.50% 72.72%
Mods (3rd gen) 22.70% 19.51% 32.50% 27.27%
Cigalike (2nd gen) 0.61% 0.81% 0.00% 0.00%
ECIG Flavor
Mint/menthol 46.47% 47.29% 43.90% 45.45%
Fruit 25.29% 26.36% 21.95% 45.45%
Sweet/dessert 10.59% 10.08% 12.20% 9.10%
Tobacco 1.18% 0.78% 2.44% 0.00%
Other 1.76% 1.55% 2.44% 0.00%
Multiple 14.71% 13.95% 17.07% 0.00%
ECIG Nicotine Concentration (mg/ml) 42.14 (23.37) 42.74 (22.84) 41.45 (24.40) 42.27 (25.23)
ECIG Days/Week 6.65 (1.08) 6.55 (1.21) 6.95 (0.31) 7.00 (0.00)
ECIG Liquid Consumption (ml) 2.14 (4.21) 1.93 (4.18) 2.79 (4.30) 2.58 (3.82)
ECIG Use Duration (months) 16.28 (13.00) 15.08 (11.82) 20.05 (15.74) 21.17 (9.32)
ECIG % Vegetable Glycerin 59.62 (11.07) 59.76 (10.79) 59.19 (11.99) 64.00 (6.58)
ECIG Wattage 28.00 (33.65) 28.02 (34.59) 27.95 (31.12) 26.60 (31.04)
PSECDI Score 8.53 (4.46) 7.95 (4.50) 10.37 (3.86) 11.91 (3.30)
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Table 4 
Mean (SD) or percentage for characteristics measured at in-person screening for completers 
    Mean (SD) or % 
Age (years)   20.63 (2.06) 
      
% Non-Hispanic   100.00% 
      
% White   63.63% 
      
% Female   63.63% 
      
% Student   63.63% 
      
Education (years)   14.00 (1.18) 
      
Lifetime Cigarettes    17.09 (29.36) 
      
Carbon Monoxide (ppm)   2.55 (1.43) 
      
MINI Tobacco-Use Disorder     
Severe   63.63% 
Moderate   18.18% 
Mild   18.18% 
      
ECIG Device Type     
Pods (4th gen)   72.72% 
Mods (3rd gen)   27.27% 
      
Nicotine Concentration (mg/ml)   42.27 (25.23) 
      
Liquid Use / Day (ml)   2.58 (3.82) 
      
Duration Use (years)   1.76 (1.59) 
      
Flavor     
Mint   45.45% 
Fruit   45.45% 
Dessert   9.10% 
      
Liquid Vegetable Glycerin (%)   64.00 (6.58) 
      
Wattage    26.60 (31.04) 
      
PSECDI Score   11.91 (3.30) 
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Table 5  
Descriptive statistics for variables considered for multiple linear regression to predict PSECDI scores 
  Mean SE Skew Zskew Kurtosis Zkurtosis 
PSECDI 
Correlation 
Age 20.96 0.31 2.88 16 9.64 26.78 0.06 
Log     2.18 12.11 5.45 15.14 0.06 
Square Root     2.52 14 7.36 20.44 0.06 
                
Lifetime Cigarettes 2652.77 1230.77 8.08 44.89 67.76 183.14 0.05 
                
Nicotine concentration 
(mg/ml) 42.13 1.79 -0.91 -4.79 -1.00 -2.70 -0.03 
Log     -1.22 -6.42 -0.22 -0.59 -0.02 
                
Days/Week 6.65 0.08 -3.42 -18 11.9 32.16 0.19* 
Log     -4.87 -25.63 27.26 73.68 0.18* 
Square Root     -4.00 -21.05 17.5 47.30 0.19* 
                
Liquid/day (ml) 2.14 0.32 3.82 20.11 18.25 49.32 0.17* 
Log     0.78 4.11 0.12 0.32 0.16* 
Square Root     1.91 10.05 2.91 7.86 0.18* 
                
Duration of use (months) 16.28 1.94 1.55 8.16 2.84 7.68 0.02 
Log     -0.84 -4.42 0.7 1.89 0.18* 
Square Root     0.36 1.89 -0.18 -0.49 0.20* 
                
Wattage 28 2.65 1.59 8.37 1.66 4.37 0.13 
Log     0.97 5.11 -0.79 -2.08 0.13 
Square Root     1.19 6.26 -0.20 -0.53 0.13 
                
PSECDI Score 8.53 0.34 -0.10 -0.53 -0.75 -2.03 - 
*	p	<	.05	              
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Table 6 
Multiple linear regression models to predict PSECDI scores. All models significantly predicted PSECDI scores, and significant 
predictors are bolded 
    F p R2 
Adjusted 
R2 AIC B SE B ß t p 
Model 1   4.39 < .001 0.18 0.14 435.81           
Age (Log)             14.44 6.42 0.21 2.25 0.026 
Smoke Status             -1.15 0.86 -0.12 -1.34 0.18 
Nicotine Concentration             0.09 0.30 0.48 2.84 0.005 
Daily ECIG Use             2.81 1.10 0.21 2.55 0.012 
Liquid Use/Day (Log)             1.33 0.99 0.16 1.34 0.18 
Duration of Use (Sqrt)             0.53 0.24 0.18 2.18 0.031 
Wattage (Sqrt)             3.80 1.53 0.37 2.48 0.014 
                        
Model 2   3.64 0.002 0.13 0.09 443.99           
Age (Log)             9.71 6.32 0.14 1.54 0.13 
Smoke Status             -0.99 0.88 -0.10 -1.13 0.26 
Daily ECIG Use             3.59 1.09 0.27 3.30 0.001 
Liquid Use/Day (Log)             0.22 0.93 0.03 0.24 0.81 
Duration of Use (Sqrt)             0.53 0.25 0.18 2.14 0.03 
Wattage (Sqrt)             0.75 1.12 0.07 0.67 0.50 
                        
Model 3   3.22 0.005 0.11 0.08 465.95           
Age (Log)             8.14 6.12 0.13 1.33 0.19 
Smoke Status             -1.07 0.85 -0.11 -1.26 0.21 
Nicotine Concentration             0.03 0.02 0.15 1.18 0.24 
Daily ECIG Use             2.8 1.10 0.21 2.55 0.012 
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Liquid Use/Day (Log)             1.48 0.99 0.18 1.50 0.14 
Duration of Use (Sqrt)             0.48 0.24 0.16 2.03 0.044 
                        
Model 4   3.40 0.006 0.10 0.07 472.72           
Age (Log)             8.04 5.91 0.13 1.36 0.18 
Smoke Status             -0.79 0.84 -0.08 -0.08 0.35 
Nicotine Concentration             0.08 0.02 0.04 0.04 0.66 
Daily ECIG Use             3.27 1.04 0.24 0.24 0.002 
Duration of Use (Sqrt)             0.53 0.23 0.18 0.18 0.02 
                        
Model 5   4.30 0.002 0.10 0.08 474.99           
Age (Log)             6.83 5.24 0.11 1.30 0.19 
Smoke Status             -0.80 0.83 -0.08 -0.97 0.34 
Daily ECIG Use             3.28 1.03 0.24 3.20 0.002 
Duration of Use (Sqrt)             0.53 0.22 0.18 2.34 0.02 
                        
Model 6   5.02 0.002 0.09 0.07 491.58           
Age (Log)             1.89 4.71 0.03 0.40 0.69 
Daily ECIG Use             3.18 1.05 0.23 3.03 0.003 
Duration of Use (Sqrt)             0.52 0.23 0.18 2.32 0.02 
                        
Model 7   4.27 0.001 0.15 0.11 454.83           
Age (Log)             7.24 6.01 0.10 1.20 0.23 
Nicotine Concentration             0.09 0.03 0.44 2.59 0.01 
Daily ECIG Use             2.78 1.14 0.20 2.44 0.02 
Liquid Use/Day (Log)             0.97 1.00 0.12 0.97 0.33 
Duration of Use (Sqrt)             0.48 0.25 0.16 1.98 0.05 
Wattage (Sqrt)             4.11 1.58 0.39 2.60 0.01 
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Table 7 
 Repeated-measures ANOVA results for heart rate and subjective outcomes. Significant main effects and interactions are bolded. 
    Conditiona   Timeb   Condition x Timeb 
        
Outcome Measure   F p ηp2   F p ηp2   F p ηp2 
Heart Rate   9.82 0.011 0.50   24.30 < 0.001 0.71   1.14 0.35 0.10 
                          
MNWS                         
Anxious   1.10 0.32 0.10   1.34 0.26 0.12   0.23 0.88 0.02 
Craving   4.24 0.07 0.30   10.36 < 0.001 0.51   4.04 0.014 0.29 
Depressed   0.10 0.76 0.01   1.54 0.23 0.13   0.38 0.70 0.04 
Difficulty Concentrating   0.53 0.48 0.05   4.79 0.002 0.32   1.57 0.20 0.14 
Drowsy   0.83 0.38 0.08   0.74 0.49 0.07   0.74 0.58 0.07 
Hunger   0.01 0.94 0.00   0.81 0.49 0.08   1.19 0.33 0.11 
Impatient   1.01 0.34 0.09   6.05 0.006 0.38   1.43 0.26 0.13 
Irritable   0.93 0.36 0.09   3.21 0.01 0.24   0.27 0.79 0.03 
Restless   4.19 0.07 0.30   2.28 0.08 0.19   1.13 0.36 0.10 
Desire Sweets   0.12 0.73 0.01   2.04 0.14 0.17   0.53 0.64 0.05 
Urges   4.83 0.053 0.33   7.14 < 0.001 0.42   2.53 0.042 0.20 
                          
QSU-Brief                         
Factor 1   2.59 0.14 0.21   8.28 0.002 0.45   1.96 0.056 0.22 
Factor 2   7.46 0.02 0.43   3.39 0.02 0.25   2.22 0.091 0.18 
                          
DENS                         
Confused   1.09 0.32 0.10   2.43 0.08 0.20   0.22 0.83 0.02 
Dizzy   2.41 0.15 0.19   5.33 0.018 0.35   1.05 0.39 0.10 
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Headache   4.56 0.06 0.31   2.10 0.17 0.17   1.15 0.35 0.10 
Heart Pound   0.30 0.60 0.03   4.45 0.02 0.31   1.41 0.26 0.12 
Lightheaded   4.90 0.051 0.33   5.98 0.02 0.37   0.67 0.60 0.06 
Nausea   3.51 0.09 0.26   3.36 0.07 0.25   0.22 0.85 0.02 
Nervous   0.58 0.46 0.06   2.31 0.09 0.19   1.36 0.28 0.12 
Salivate   0.01 0.93 0.00   2.37 0.11 0.19   0.31 0.81 0.03 
Sweaty   0.11 0.74 0.01   0.63 0.52 0.06   1.13 0.35 0.10 
Weak   0.81 0.39 0.08   2.97 0.11 0.23   3.22 0.042 0.24 
                          
DEPS                         
Awake   1.02 0.34 0.09   0.77 0.50 0.07   1.29 0.28 0.11 
Calm   3.98 0.07 0.29   3.85 0.003 0.28   0.52 0.69 0.05 
Concentrate   1.80 0.21 0.15   1.03 0.41 0.09   0.61 0.67 0.06 
Dizzy   0.14 0.71 0.01   1.76 0.18 0.15   0.83 0.50 0.08 
Pleasant   3.50 0.09 0.26   3.29 0.08 0.25   3.61 0.034 0.27 
Reduced Hunger   0.69 0.43 0.06   0.90 0.45 0.08   1.14 0.35 0.10 
Satisfy   3.91 0.08 0.28   2.16 0.14 0.18   3.72 0.016 0.27 
Sick    0.82 0.39 0.08   1.05 0.39 0.10   0.38 0.66 0.04 
Taste Good   3.64 0.09 0.27   2.65 0.11 0.21   2.07 0.16 0.17 
a df = 1,10; b Heart Rate df = 7,70; Subjectives df =  6,60                 
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Table 8 
Mean (SD) for best cognitive performance during training. 
          
          
      Mean (SD)   
  RVIP       
  % Correct   54.72 (16.58)   
  Reaction Time   510.65 (95.93)   
  Errors Commission   8.09 (10.15)   
  Errors Omission   21.73 (8.01)   
          
  N-back       
  2-back Accuracy   97.82 (4.49)   
  3-back Accuracy   67.14 (14.30)   
  2-back Reaction Time   484.49 (104.87)   
  3-back Reaction Time   600.77 (112.58)   
          
  Cued Go/No-Go       
  No-Go Congruent Accuracy   98.55 (3.36)   
  No-Go Incongruent Accuracy   98.73 (1.90)   
  Go Reaction Time   328.69 (27.51)   
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Table 9 
Paired-samples t-test results comparing 120 minutes ECIG abstinence to baseline ECIG abstinence and 120 minutes ad lib ECIG use 
    
120 min abstinence - Baseline abstinence 
  
120 minutes abstinence - 120 minutes ad lib 
      
    t p d   t p d 
RVIP                 
% Correct   -1.16 0.27 0.20   0.62 0.55 0.14 
Reaction Time   0.94 0.37 0.15   -0.53 0.61 0.15 
Errors Commission   0.52 0.62 0.10   -0.89 0.49 0.22 
Errors Omission   1.17 0.27 0.20   -0.63 0.54 0.14 
                  
N-back                 
2-back Accuracy   -1.08 0.30 0.30   0.23 0.82 0.07 
3-back Accuracy   3.64 0.005 0.87   2.04 0.07 0.44 
2-back Reaction Time   -1.61 0.14 0.26   0.45 0.66 0.11 
3-back Reaction Time   0.81 0.94 0.02   0.34 0.74 0.06 
                  
Cued Go/No-Go                 
No-Go Congruent Accuracy   0.80 0.44 0.36   0.00 1.00 0.00 
No-Go Incongruent Accuracy   -3.99 0.003 1.08   -2.68 0.023 0.90 
Go Reaction Time   0.73 0.48 0.13   -0.64 0.54 0.014 
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Table 10 
Mean (SE) cognitive performance for the ad lib and abstinent conditions at baseline and 120 minutes 
    Ad lib   Abstinent 
      
    Baseline 120 minutes   Baseline 120 minutes 
RVIP             
% Correct   50.55 (4.10) 49.45 (4.57)   55.27 (5.24) 51.72 (5.49) 
Reaction Time   433.03 (12.72) 464.57 (22.25)   463.49 (16.53) 454.37 (20.07) 
Errors Commission   3.27 (1.38) 4.18 (1.62)   5.00 (2.16) 5.81 (2.71) 
Errors Omission   23.72 (1.96) 24.27 (2.17)   21.45 (2.51) 23.18 (2.63) 
              
N-back             
2-back Accuracy   93.45 (2.19) 89.27 (3.40)   93.27 (3.07) 90.09 (3.33) 
3-back Accuracy   54.63 (4.46) 57.90 (8.53)   51.09 (5.95) 69.00 (6.49) 
2-back Reaction Time   483.40 (33.29) 506.61 (32.76)   487.93 (35.29) 519.47 (35.82) 
3-back Reaction Time   540.03 (52.78) 591.45 (51.97)   598.20 (32.22) 599.79 (31.78) 
              
Cued Go/No-Go             
No-Go Congruent Accuracy   98.55 (0.81) 99.64 (0.36)   98.91 (0.78) 99.64 (0.36) 
No-Go Incongruent Accuracy   98.82 (0.42) 98.73 (0.41)   99.00 (0.40) 97.36 (0.51) 
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Table 11 
Mean (SD) change in cognitive performance from baseline to 120 minutes for the ad lib and 
abstinent conditions 
    Ad lib   Abstinent 
RVIP         
% Correct   -1.09 (10.90)   -3.55 (10.16) 
Reaction Time   31.54 (64.36)   -9.11 (32.17) 
Errors Commission   .91 (1.64)   .82 (5.27) 
Errors Omission   .55 (5.13)   1.73 (4.90) 
          
N-back         
2-back Accuracy   -4.18 (12.84)   -3.18 (9.73) 
3-back Accuracy   3.27 (19.66)   17.91 (16.31) 
2-back Reaction Time   23.21 (79.61)   31.54 (65.13) 
3-back Reaction Time   51.41 (106.64)   1.59 (64.72) 
          
Cued Go/No-Go         
No-Go Congruent Accuracy   1.09 (3.14)   0.73 (3.00) 
No-Go Incongruent Accuracy   -.09 (1.87)   -1.64 (1.36) 
Go Reaction Time   1.81 (16.13)   4.87 (22.20) 
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Table 12 
Mean (SD) cognitive performance for session 1 and session 2 at baseline and 120 minutes 
    Session 1   Session 2 
      
    Baseline 120 minutes   Baseline 120 minutes 
RVIP             
% Correct   53.27 (16.79) 52.91 (14.77)   52.55 (14.70) 48.27 (18.29) 
Reaction Time   441.01 (53.34) 464.37 (73.40)   455.51 (48.33) 454.57 (67.04) 
Errors Commission   4.72 (7.32) 5.91 (8.88)   3.55 (4.44) 4.09 (5.54) 
Errors Omission   22.45 (8.04) 22.63 (7.05)   22.73 (7.06) 24.82 (8.75) 
              
N-back             
2-back Accuracy   95.27 (7.72) 92.73 (10.30)   91.45 (9.44) 86.64 (11.11) 
3-back Accuracy   54.27 (17.62) 63.91 (25.12)   51.45 (17.33) 63.00 (26.47) 
2-back Reaction Time   490.81 (112.35) 492.86 (93.74)   480.52 (114.99) 533.23 (127.76) 
3-back Reaction Time   587.01 (146.09) 605.72 (151.85)   551.23 (147.92) 585.52 (132.59) 
              
Cued Go/No-Go             
No-Go Congruent Accuracy   98.55 (2.70) 99.64 (1.21)   98.91 (2.59) 99.64 (1.21) 
No-Go Incongruent Accuracy   99.36 (0.92) 98.55 (1.57)   98.45 (1.57) 97.55 (1.63) 
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Table 13 
Mean (SE) MCP crossover point for the ad lib and abstinence conditions at baseline, 75 minutes, 
and 150 minutes 
  Baseline 75 min 150 min 
Ad lib 1.73 (0.57) 1.47 (0.44) 1.76 (0.54) 
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Table 14 









    
Participant 1 puff 2 - 5 puffs 6 - 10 puffs > 10 puffs 2 - 5 puffs 6 - 10 puffs > 10 puffs 1 puff 2 - 5 puffs 6 - 10 puffs > 10 puffs
501 4 13 2 0 3.85 6.00 n/a 6.15 76.92 18.46 0.00
502 24 21 0 0 2.43 n/a n/a 32.00 68.00 0.00 0.00
504 19 16 0 0 2.44 n/a n/a 32.76 67.24 0.00 0.00
505 0 13 3 0 3.62 7.67 n/a 0.00 61.04 29.87 0.00
507 17 1 0 0 2.00 n/a n/a 88.24 11.76 0.00 0.00
510 22 5 0 0 2.60 n/a n/a 62.86 37.14 0.00 0.00
513 28 9 0 0 2.44 n/a n/a 56.00 44.00 0.00 0.00
514 27 12 0 0 2.67 n/a n/a 45.76 54.24 0.00 0.00
515 15 3 1 0 2.33 6.00 n/a 53.57 24.00 21.43 0.00
Mean 17.33 10.33 0.67 0.00 2.71 6.56 n/a 41.93 49.37 7.75 0.00
SD 9.75 6.46 1.12 0.00 0.61 0.96 n/a 27.73 21.86 12.00 0.00
Frequency of puff clusters Average number of puffs per cluster Percent of total puffs in session (%)
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Table 15 
Multiple linear regressions to predict withdrawal based on puff topography. Significant models and predictors are blooded. 
    R R2 F p B SE B ß t p 
Heart Rate   0.42 0.18 2.93 0.03           
Puff Number           0.74 0.44 0.43 1.69 0.10 
Puff Duration           -2.76 1.05 -0.33 -2.52 0.011 
IPI           -0.003 0.003 -0.13 -0.89 0.38 
Cluster           -3.35 1.48 -0.54 -2.27 0.03 
                      
MNWS                     
Anxious   0.32 0.11 1.59 0.19           
Puff Number           -0.62 0.53 -0.31 -1.17 0.25 
Puff Duration           2.60 1.27 0.27 2.05 0.046 
IPI           -0.004 0.003 -0.19 -1.23 0.224 
Cluster           2.06 1.78 0.29 1.16 0.25 
                      
Craving   0.48 0.23 3.92 0.007           
Puff Number           1.65 1.15 0.36 1.44 0.16 
Puff Duration           8.03 2.75 0.36 2.92 0.005 
IPI           0.02 0.008 0.36 2.46 0.017 
Cluster           0.07 3.85 0.004 0.02 0.99 
                      
Depressed   0.16 0.03 0.34 0.85           
Puff Number           0.08 0.32 0.07 0.02 0.98 
Puff Duration           0.22 0.77 0.04 0.29 0.78 
IPI           -0.002 0.002 -0.16 -0.96 0.34 
Cluster           -0.47 1.07 -0.11 -0.44 0.66 
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Difficulty Concentrate   0.29 0.08 1.24 0.31           
Puff Number           -1.06 0.92 -0.31 -1.16 0.25 
Puff Duration           4.12 2.2 0.25 1.88 0.07 
IPI           -0.005 0.006 -0.14 -0.91 0.37 
Cluster           3.39 3.08 0.28 1.1 0.28 
                      
Drowsy   0.58 0.33 6.71 <.001           
Puff Number           -1.27 1.12 -0.26 -1.13 0.26 
Puff Duration           11.75 2.69 0.49 4.37 < .001 
IPI           -0.02 0.007 -0.32 -2.39 0.021 
Cluster           0.31 3.77 0.017 0.081 0.94 
                      
Hunger   0.54 0.29 5.53 0.001           
Puff Number           -1.15 1.25 -0.22 -0.92 0.36 
Puff Duration           11.42 3.01 0.44 3.80 < .001 
IPI           -0.01 0.008 -0.17 -1.24 0.22 
Cluster           8.60 4.21 0.45 2.04 0.046 
                      
Impatient   0.65 0.42 9.93 < .001           
Puff Number           0.35 0.70 0.11 0.50 0.62 
Puff Duration           10.08 1.67 0.64 6.05 < .001 
IPI           0.003 0.005 0.08 0.62 0.54 
Cluster           2.04 2.34 0.17 0.87 0.39 
                      
Irritable   0.40 0.16 2.54 0.05           
Puff Number           -0.75 0.37 -0.53 -2.05 0.046 
Puff Duration           2.10 0.88 0.30 2.39 0.021 
IPI           -0.003 0.002 -0.18 -1.21 0.23 
Cluster           2.69 1.23 0.52 2.18 0.033 
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Restless   0.34 0.12 1.80 0.14           
Puff Number           -0.50 0.89 -0.15 -0.56 0.58 
Puff Duration           5.48 2.13 0.34 2.58 0.013 
IPI           -0.004 0.006 -0.11 -0.68 0.50 
Cluster           1.88 2.98 0.16 0.63 0.53 
                      
Desire Sweets   0.38 0.14 2.26 0.074           
Puff Number           -0.43 1.46 -0.08 -0.30 0.77 
Puff Duration           6.66 3.49 0.24 1.91 0.06 
IPI           -0.01 0.01 -0.12 -0.79 0.43 
Cluster           6.45 4.90 0.32 1.32 0.19 
                      
Urges   0.36 0.13 2.02 0.11           
Puff Number           0.98 1.19 0.22 0.82 0.41 
Puff Duration           4.25 2.85 0.19 1.49 0.14 
IPI           0.02 0.01 0.36 2.33 0.02 
Cluster           -1.62 3.99 -0.1 -0.41 0.69 
                      
QSU-Brief                     
Factor 1   0.35 0.13 2.04 0.1           
Puff Number           0.44 0.34 0.34 1.30 0.20 
Puff Duration           1.08 0.81 0.17 1.33 0.19 
IPI           0.004 0.002 0.24 1.57 0.12 
Cluster           0.30 1.14 0.07 0.27 0.79 
                      
Factor 2   0.30 0.09 1.31 0.28           
Puff Number           0.06 0.14 0.12 0.43 0.67 
Puff Duration           0.73 0.34 0.29 2.19 0.03 
IPI           0.0003 0.001 0.06 0.39 0.70 
Cluster           -0.006 0.47 -0.003 -0.01 0.99 
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DENS                     
Confused   0.33 0.11 1.60 0.19           
Puff Number           -0.40 0.25 -0.43 -1.60 0.12 
Puff Duration           -0.26 0.59 -0.06 -0.44 0.66 
IPI           -0.002 0.002 -0.18 -1.13 0.26 
Cluster           1.72 0.83 0.51 2.07 0.04 
                      
Dizzy   0.26 0.07 0.96 0.44           
Puff Number           -1.95 1.31 -0.41 -1.49 0.14 
Puff Duration           1.09 3.14 0.05 0.35 0.73 
IPI           -0.01 0.009 -0.23 -1.44 0.16 
Cluster           6.35 4.40 0.37 1.44 0.16 
                      
Headache   0.30 0.09 1.35 0.27           
Puff Number           -0.78 0.78 -0.27 -1.01 0.32 
Puff Duration           2.57 1.86 0.18 1.39 0.17 
IPI           -0.008 0.005 -0.25 -1.61 0.11 
Cluster           0.39 2.61 0.04 0.15 0.88 
                      
Heart Pound   0.21 0.04 0.61 0.66           
Puff Number           -0.20 0.54 -0.10 -0.38 0.71 
Puff Duration           0.64 1.30 0.07 0.50 0.62 
IPI           -0.005 0.004 -0.23 -1.43 0.16 
Cluster           0.12 1.83 0.02 0.07 0.95 
 
                      
Lightheaded   0.28 0.08 1.15 0.34           
Puff Number           -1.64 1.19 -0.37 -1.37 0.18 
Puff Duration           0.33 2.86 0.02 0.12 0.91 
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IPI           -0.01 0.008 -0.23 -1.47 0.15 
Cluster           6.25 4.01 0.39 1.56 0.13 
                      
Nausea   0.23 0.05 0.74 0.57           
Puff Number           -1.18 0.97 -0.34 -1.21 0.23 
Puff Duration           0.63 2.33 0.04 0.27 0.79 
IPI           -0.008 0.006 -0.20 -1.26 0.21 
Cluster           4.03 3.27 0.31 1.23 0.22 
                      
Nervous   0.44 0.19 3.16 0.02           
Puff Number           -1.03 0.35 -0.76 -2.98 0.004 
Puff Duration           0.56 0.83 0.08 0.67 0.50 
IPI           -0.004 0.002 -0.27 -1.83 0.07 
Cluster           3.72 1.16 0.75 3.2 0.002 
                      
Salivate   0.42 0.18 2.87 0.03           
Puff Number           -0.37 0.37 -0.26 -1.00 0.32 
Puff Duration           -0.09 0.89 -0.01 -0.10 0.92 
IPI           -0.004 0.002 -0.25 -1.64 0.11 
Cluster           2.50 1.25 0.48 2.00 0.05 
                      
Sweaty   0.33 0.11 1.66 0.17           
Puff Number           -0.61 0.51 -0.32 -1.19 0.24 
Puff Duration           -2.10 1.22 -0.22 -1.71 0.09 
IPI           -0.003 0.003 -0.15 -0.98 0.33 
Cluster           2.37 1.72 0.34 1.38 0.17 
                      
Weak   0.18 0.03 0.45 0.78           
Puff Number           -0.01 0.48 -0.01 -0.02 0.98 
Puff Duration           0.08 1.16 0.01 0.07 0.95 
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IPI           -0.004 0.003 -0.20 -1.20 0.23 
Cluster           -0.30 1.63 -0.05 -0.19 0.85 
                      
DEPS                     
Awake   0.40 0.16 2.61 0.05           
Puff Number           -0.88 0.90 -0.26 -0.99 0.33 
Puff Duration           -3.79 2.15 0.22 -1.76 0.08 
IPI           -0.01 0.006 -0.29 -1.89 0.06 
Cluster           3.85 3.02 0.31 1.27 0.21 
                      
Calm   0.17 0.03 0.39 0.82           
Puff Number           -0.93 1.21 -0.22 -0.77 0.44 
Puff Duration           2.37 2.89 0.22 0.82 0.42 
IPI           -0.005 0.008 -0.11 -0.65 0.52 
Cluster           1.40 4.06 0.09 0.35 0.73 
                      
Concentrate   0.60 0.36 7.64 < .001           
Puff Number           -0.77 0.96 -0.18 -0.80 0.43 
Puff Duration           -10.08 2.29 -0.49 -4.40 < .001 
IPI           -0.008 0.006 -0.16 -1.22 0.23 
Cluster           5.38 3.21 0.35 1.68 0.10 
                      
Dizzy   0.15 0.02 0.3 0.88           
Puff Number           -1.69 1.68 -0.28 -1.01 0.32 
Puff Duration           -0.59 4.02 -0.02 -0.15 0.88 
IPI           -0.007 0.01 -0.10 -0.60 0.55 
Cluster           3.32 5.64 0.15 0.59 0.56 
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Pleasant   0.42 0.18 2.97 0.03           
Puff Number           1.10 1.08 0.26 1.02 0.32 
Puff Duration           -3.61 2.60 -0.17 -1.39 0.17 
IPI           0.01 0.007 0.26 1.72 0.09 
Cluster           2.88 3.64 0.19 0.79 0.43 
                      
Reduced Hunger   0.48 0.23 4.13 0.005           
Puff Number           -1.70 1.04 -0.40 -1.63 0.11 
Puff Duration           -7.30 2.49 -0.35 -2.93 0.005 
IPI           -0.014 0.007 -0.29 -2.03 0.047 
Cluster           5.54 3.50 0.36 1.59 0.12 
                      
Satisfy   0.42 0.18 2.91 0.03           
Puff Number           1.05 1.06 0.26 0.99 0.33 
Puff Duration           -2.51 2.54 -0.12 -0.99 0.33 
IPI           0.01 0.007 0.25 1.67 0.10 
Cluster           3.27 3.56 0.22 0.92 0.36 
                      
Sick   0.32 0.10 1.51 0.21           
Puff Number           -1.21 1.25 -0.26 -0.97 0.34 
Puff Duration           4.02 3.00 0.18 1.34 0.19 
IPI           -0.003 0.008 -0.05 -0.33 0.74 
Cluster           -0.36 4.20 -0.02 -0.09 0.93 
                      
Taste Good   0.41 0.16 2.66 0.04           
Puff Number           1.39 1.34 0.27 1.03 0.31 
Puff Duration           -4.95 3.22 -0.19 -1.54 0.13 
IPI           0.014 0.009 0.234 1.55 0.13 
Cluster           2.71 4.52 0.14 0.60 0.55 
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Figure 2. Rapid Visual Information Processing task diagram. Panel A demonstrates a target, as 
demonstrated by the presentation of three consecutive even (or odd) digits. A response to the 
target is defined as a correct response. Panel B demonstrates a non-target, as demonstrated by the 
lack of presentation of three consecutive even or odd digits. A response on the non-target is 
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Figure 3. N-back task diagram. Panel A demonstrates the 2-back condition. A target is a stimulus 
that is identical to the stimulus presented two letters prior. A “yes” response to the target is 
considered a hit, while a “no” response is an incorrect response. Panel B demonstrates the 3-back 
condition. A target is a stimulus that is identical to the stimulus presented three letters prior. A 
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Figure 4. Cued Go/No-Go task diagram. For the purposes of this figure, green rectangles are 
represented in black and blue rectangles are represented in gray. Panel A demonstrates a 
congruent Go target. A Go cue is presented as a vertical rectangle. The go target is represented 
by the black (green) fill. The target is congruent because the cue and the target indicate it is a Go 
trial. Panel B demonstrates an incongruent Go target. A No-Go cue is presnted as a horizontal 
rectangle. The Go target is represented by the black (green) fill. The target is incongruent 
because the cue indicates a No-Go trial, but the target requires a Go response. Panel C 
demonstrates a congruent No-Go target. A No-Go cue is presented as a horizontal rectangle. The 
No-Go target is represented by the gray (blue) fill. The target is congruent because the cue and 
the target indicate it is as No-Go trial. Panel D demonstrates an incongruent No-Go target. A Go 
cue is presented as a vertical rectangle. A No-Go target is represented by the gray (blue) fill. The 
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Figure 5. Diagram of recruitment, enrollment, reasons for ineligibility, and number of 




































PSECDI < 7 (n = 57)
Past month marijuana > 10 days (n = 44)
Past year cigarettes > 10 (n = 28)
Past month cigarettes > 2 (n = 16)
Nondaily ECIG use (n = 17)
Psychiatric/medical problems (n = 12)
Past month illicit substance (n = 9)
Incomplete survey (n = 8)
Age < 18 or > 40 (n = 2)
Use ECIG without nicotine (n = 1)
Past month alcohol > 25 days (n = 1)
PSECDI < 7 (n = 3)
Past month marijuana use > 10 days (n = 2)
Past year cigarette > 10 (n = 1)
Failure to provide urine sample (n = 1)
Dropout
n = 4
























Figure 6. Mean heart rate during 180 minutes of ad lib ECIG use or ECIG abstinence. The error 










































Figure 7. Mean ratings for MNWS craving during 180 minutes of ad lib ECIG use or ECIG 







































Figure 8. Mean ratings for QSU-Brief Factor 1 (intention to smoke) during 180 minutes of ad lib 







































Figure 9. Mean ratings for DENS weak during 180 minutes of ad lib ECIG use or ECIG 









































Figure 10. Mean ratings for DEPS pleasant during 180 minutes of ad lib ECIG use or ECIG 




























































Figure 11. Mean RVIP percent correct for ad lib and abstinent conditions at baseline and 120 
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Figure 12. Mean 3-back accuracy for ad lib and abstinent conditions at baseline and 120 
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Figure 13. Mean No-Go incongruent accuracy for ad lib and abstinent conditions at baseline and 
























Figure 14. Puffing patterns in the ad lib condition for participant 501. Participant 501 used a 3rd generation mod at 50 watts, with a 
berry-flavored liquid with 3 mg/ml nicotine. Boxes represent a puff cluster with the number above indicating the number of puffs in 
the cluster. 
0 10 20 30 40 50 60
501 Puffs: Time 0 - 60 min
54
60 70 80 90 100 110 120
501 Puffs: Time 60 - 120 min
4 3 4 6 3 3 6 2 3
120 130 140 150 160 170 180
501 Puffs: Time 120 - 180 min
5233
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Figure 15. Puffing patterns in the ad lib condition for participant 507. Participant 507 used a 4th generation pod (Juul) at 8 watts, with 
a mint-flavored liquid with 59 mg/ml nicotine. Boxes represent a puff cluster with the number above indicating the number of puffs in 
the cluster. 
 
0 10 20 30 40 50 60
507 Puffs: Time 0 - 60 minutes
60 70 80 90 100 110 120
507 Puffs: Time 60 - 120 minutes
120 130 140 150 160 170 180
507 Puffs: Time 120 - 180 minutes
2




Figure 16. Puffing patterns in the ad lib condition for participant 513. Participant 513 used a 4th generation pod (Juul) at 8 watts, with 
a mint-flavored liquid with 59 mg/ml nicotine. Boxes represent a puff cluster with the number above indicating the number of puffs in 
the cluster. 
0 10 20 30 40 50 60
513 Puffs: Time 0 – 60 minutes
2 2 2
60 70 80 90 100 110 120
513 Puffs: Time 60 – 120 minutes
2 2 2
120 130 140 150 160 170 180
513 Puffs: Time 120 – 180 minutes
5 2
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Figure 17. Puffing patterns, heart rate, and MNWS urges for participant 501 in the ad lib 
condition. Participant 501 used a 3rd generation mod at 50 watts, with a berry-flavored liquid 
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Figure 18. Puffing patterns, heart rate, and MNWS urges for participant 507 in the ad lib 
condition. Participant 507 used a 4th generation pod (Juul) at 8 watts, with a mint-flavored liquid 
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Figure 19. Puffing patterns, heart rate, and MNWS urges for participant 513 in the ad lib 
condition. Participant 513 used a 4th generation pod (Juul) at 8 watts, with a mint-flavored liquid 
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Appendix A 
Telephone Screening Questionnaire 
 
Date: _______________     Interviewer: _______________ 
 
Interviewer:  “I would like to ask you some questions about yourself and your health status as 
well as your use of tobacco, alcohol, and other drugs. The purpose of these questions is to 
determine whether or not you are eligible to participate in the study that I just described to you.  
All of your responses are confidential.  You are not required to answer any question and you may 
stop this interview at any time. May I begin the questions?” 
Document caller’s response by circling either:    Yes      or      No 
 
If Yes: begin form.  If No: thank the caller and stop the interview. 
--------------------------------------------------------------------------------------------------------------------- 
 




1.  “What is your first name?”      ________________________ 
 
2.  “What is a phone number/email at which you can be contacted?” _______________________ 
 
3.  “If we call and you are not available, may we leave a message?”   Yes      or      No 
 
4.  “What is your date of birth?”      ________________________  
 
 
General health status: 
 
1.  “Are you currently under a doctor’s care for a medical condition?” Yes      or      No 
 
  If Yes: “Please describe the concern or problem”: 
 
2.  “Do you have any chronic health concerns or problems?”   Yes      or      No 
 
  If Yes: “Please describe the condition”: 
 
3.  “Are you taking any prescription or over-the-counter medications?” Yes      or      No 
 
  If Yes: “Please identify the medication”: 
 
4.  Have you been diagnosed with any psychiatric conditions like bipolar disorder or 
schizophrenia?         Yes      or      No 
  If Yes: “Please describe the condition”: 
 
For women only: 
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6.  “Are you currently pregnant?”      Yes      or      No 
 




1.  “Have you ever smoked tobacco cigarettes?”    Yes      or      No 
 
2. “Do you currently smoke tobacco cigarettes?”    Yes      or      No 
 
3.  “How many cigarettes have you smoked in your lifetime?” __________(numb of cigs) 
 
4. “How many cigarettes have you smoked in the past year?”  __________(numb of cigs) 
 




Electronic Cigarette Use: 
 
1.  “Do you currently use an electronic cigarette?” Yes      or      No 
If No: Skip to the section on other tobacco use 
 
2.  “What model/brand of ECIG do you own?   ____________________ 
   
  a) If own multiple, which do you use most frequently?   ____________________ 
 
3.  “What nicotine concentration of e-liquid do you use?”  _________________(mg/ml) 
 
4.  “What flavor of e-liquid do you use?”    ____________________ 
 
5.  “On average, how many days per week do you use an ECIG?” ____________________ 
 
6.  “How much e-liquid/How many cartridges do you use per day? ________________(ml or #) 
 
[Guide to report one number that best represents their average/day; do not provide a 
range] 
 
7.  “For how long have you used that amount of product?”   __________(months / years) 
 
8. What ratio of propylene glycol : vegetable glycerin do you use?        ___________(% pg : % 
vg) 
 
9. At what wattage do you typically vape?                                            ______________ (Watts) 
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1. How many times per day do you usually use your electronic cigarette? (assume that one 
time consists of around 15 puffs or lasts around 10 minutes)  
 
a. 0-4             b. 5-9  c. 10-14 d. 15-19 e. 20-20 f. 30+ 
 
2. How soon after you wake up do you first use your electronic cigarette?    
 
a. 0-5 min b. 6-15 min   c. 16-30 min     d. 31-60 min      e. 121+ 
min 
 
3. Do you sometimes awaken at night to use your electronic cigarette?         
 
a. Yes  b. No 
 
4. If yes, how many nights per week do you typically awaken to use your electronic 
cigarette? 
 
a. 0-1 night  b. 2-3 nights  c. 4+ nights 
 
5. Do you use an electronic cigarette now because it is really hard to quit?    
 
a. Yes  b. No 
 
6. Do you ever have strong cravings to use an electronic cigarette?  
 
a. Yes  b. No 
 
7. Over the past week, how strong have the urges to use an electronic cigarette been? 
 
a. None/Slight  b. Moderate/Strong  c. Very/Extremely Strong 
 
8. Is it hard to keep from using an electronic cigarette in places where you’re not supposed 
to? 
 
a. Yes  b. No 
 
9. Did you feel more irritable because you couldn’t use an electronic cigarette?  
 
a. Yes  b. No 
 
10. Did you feel nervous, restless, or anxious because you couldn’t use an electronic cigarette 
 
a. Yes  b. No 
--------------------------------------------------------------------------------------------------------------------- 
Other Tobacco Use: 
 
1.  “Have you used any of the following other nicotine/tobacco products in the past month?”   
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If ‘yes’, estimate how many days 
you have used this product in the 
past month? 
Large cigars No Yes  
Cigarillos (e.g., Black & Milds) 
or small cigars 
No Yes  
Waterpipe (a.k.a. hookah or 
shisha) 
No Yes  
Smokeless tobacco 
(snuff/dip/chew/snus) 
No Yes  
Cigarettes No Yes  




Smoking Cessation History: 
 
1. “Are you currently using any nicotine replacement products?”   Yes      or      No 
      (e.g., patch, gum, inhaler, nasal spray) 
 
2. “Are you currently using any prescription medications for cessation?”  Yes      or      No 
    (e.g., Chantix, Zyban, etc.) 
--------------------------------------------------------------------------------------------------------------------- 
Illicit Drug Use: 
 
1. “Have you used any of the following other drugs for recreational purposes in the past 
month?” 
 
   If ‘yes’, estimate how many days 
you have used this product in the 
past month? 
Alcohol No Yes 
 
Marijuana / Spice / K2 No Yes  
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Interviewer:  “Thank you for responding to these questions.  I need to pass on your responses to 
the principal investigator who will then determine whether or not you are eligible to participate 
in a study.  If you are eligible, someone will contact you within approximately one week. If you 
are not eligible for this study, then you will not be contacted.” 
 




























































o American Indian/Alaskan Native  o Asian  o White     
 
o  Native Hawaiian or other Pacific Islander  
 





o Male    o Female    o Other/Wish Not to Report 
______________________________________________________________________________  
Marital status  
 




Years: __________ (For example, High school = 12, College degree = 16, etc.)  
______________________________________________________________________________  
Primary employment  
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Appendix C 
Health and Drug Use Form 
 
 Participant ID: ___________      Date: ______________ 
 
 General health status:  
 
Are you under a doctor’s care for a medical condition?_______ (If yes, please describe below)  
 
Are you taking any prescription medications? ________ (If yes, please identify below)  
 
Do you have any chronic health concerns or problems?________ (If yes, please describe below)  
 
Have you been diagnosed with any psychiatric conditions such as schizophrenia or bipolar 
disorder?      ________ (If yes, please describe below)  
 
For women only:  
 
Are you currently pregnant? _______ (yes or no)  
 
Are you currently breast-feeding a child? ______ (yes or no)  
 
Cigarette Use:  
 
Have you ever smoked tobacco cigarettes? ________ (yes or no) 
 
Do you currently smoke tobacco cigarettes? ________ (yes or no)  
 
How many cigarettes have you smoked in your lifetime?  _______________ (# of cigarettes)  
 
How many cigarettes have you smoked in the past year? _______________ (# of cigarettes) 
 




Do you currently use an ECIG?   ________ (yes or no) if no, skip to the next section 
 
How many days per week do you use an ECIG? __________________ (number of days) 
 
On average, how much e-liquid/how many cartridges do you use per day? ___________(ml or #)  
 
What nicotine concentration of e-liquid do you use? __________________ (mg/ml or %) 
 
For how long have you been using an ECIG?  _________________ (months/years) 
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What model ECIG do you use most frequently?  __________________  
 
What flavor of e-liquid do you use most frequently? _________________  
 
What ratio of propylene glycol : vegetable glycerin do you use? ____________ (% PG : % VG) 
 




1. How many times per day do you usually use your electronic cigarette? (assume that one 
time consists of around 15 puffs or lasts around 10 minutes)  
a. 0-4             b. 5-9  c. 10-14 d. 15-19 e. 20-20 f. 30+ 
 
2. How soon after you wake up do you first use your electronic cigarette?    
a. 0-5 min b. 6-15 min   c. 16-30 min     d. 31-60 min      e. 121+ 
min 
 
3. Do you sometimes awaken at night to use your electronic cigarette?         
a. Yes  b. No 
 
4. If yes, how many nights per week do you typically awaken to use your electronic 
cigarette? 
a. 0-1 night  b. 2-3 nights  c. 4+ nights 
 
5. Do you use an electronic cigarette now because it is really hard to quit?    
a. Yes  b. No 
 
6. Do you ever have strong cravings to use an electronic cigarette?  
a. Yes  b. No 
 
7. Over the past week, how strong have the urges to use an electronic cigarette been? 
a. None/Slight  b. Moderate/Strong  c. Very/Extremely Strong 
 
8. Is it hard to keep from using an electronic cigarette in places where you’re not supposed 
to? 
a. Yes  b. No 
 
9. Did you feel more irritable because you couldn’t use an electronic cigarette?  
a. Yes  b. No 
 
10. Did you feel nervous, restless, or anxious because you couldn’t use an electronic cigarette 
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History of Quit Attempts:  
 
Have you ever made an attempt to quit or reduce your ECIG use? ____________ (yes or no) if 
no, skip to the next section  
 
Have you made any attempts to quit or reduce your ECIG use in the last 30 days? ____________  
 
Other Tobacco Use:  
 
Do you currently use any other nicotine/tobacco products? ____________ (yes or no)  
 
Circle all products below that you have used in the past 30 days:  
 
Cigars / cigarillos / small cigars   Smokeless tobacco (snuff, dip, chew) / snus 
 
Hookah / waterpipe     Cigarettes 
 
Nicotine gum / patch / lozenge / inhaler  Other: ________________________ 
 
Alcohol Use:  
 
Have you used alcohol in the past month? ________ (yes or no) if no, skip to the next section  
 
How many days out of the last 30 have you used alcohol? __________________ (number of 
days)  
 
Have you ever been treated for alcohol abuse/dependence? __________________ (yes or no)  
 
Other Drug Use:  
 
Have you used marijuana in the past month? ________ (yes or no) if no, skip to the next section  
 
How many days out of the last 30 have you used marijuana? __________________ (number of 
days)  
 
Have you ever been treated for marijuana abuse/dependence? __________________ (yes or no) 
 
Have you used any illegal drugs within the past month? ________ (yes or no)  
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Appendix D 
MINI Tobacco Use Disorder Screen for ECIGs 
 
J2: Considering your use of ECIGs, in the past 12 
months:   
            
  
a. During times when you used the drug, did you end 
up using more than you planned when you started? 
        
    No   Yes 
          
            
  b. Did you repeatedly want to reduce or control your 
ECIG use? Did you try to cut down or control your 
ECIG use, but failed? 
        
    No   Yes 
          
  (If yes to either, code YES)         
            
  c. On the days that you used more ECIG, did you 
spend substantial time obtaining, using it, or 
recovering from its effects? 
        
    No   Yes 
          
            
  
d. Did you crave or have a strong desire or urge to 
use ECIGs? 
        
    No   Yes 
          
            
  e. Did you spend less time meeting your 
responsibilities at work, school, or at home, because 
of your repeated ECIG use? 
        
    No   Yes 
          
            
  
f. If your ECIG use caused problems with your 
family or other people, did you still keep on using it? 
        
    No   Yes 
          
            
  
g. Did you use the drug more than once in any 
situation where you or others were physically at risk 
(e.g., driving, riding motorbike, using machinery, 
etc.) 
        
    No   Yes 
          
          
            
  
h. Did you continue to use ECIGs, even though it 
was clear that ECIGs had caused or worsened 
psychological or physical problems? 
        
    No   Yes 
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i. Did you reduce or give up important work, social, 
or recreational activities because of your ECIG use? 
        
    No   Yes 
          
  
j. Did you need to use ECIGs a lot more in order to 
get the same effect that you got when you first started 
using it, or did you get much less effect with 
continued use of the same amount? 
        
          
    No   Yes 
          
          
            
K1: When you cut down on heavy or prolonged use of the drug, did you have any of the 
following side effects: 
  (Choose yes if 3 or more of the following)   No   Yes 
            
    
Check box if says YES to each of 
following 
  1. Irritability, frustration, anger         
            
  2. anxiety         
            
  3. difficulty concentrating         
            
  4. increased appetite         
            
  5. restlessness         
            
  6. feeling depressed         
            
  7. difficulty sleeping         
            
K2: Did you use ECIGs to reduce or avoid withdrawal 
symptoms? No   Yes 
            
K Summary: If YES to K1 or K2, code YES   No   Yes 
            
Are 2 or more answers from J2 through K Summary 
coded YES? No   Yes 
  Yes = ECIG use disorder         
  No = No disorder         
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Severity of SUD (Ja-j, Ksummary)   Choose 1 Severity 
            
  Mild = 2-3 of symptoms     MILD   
            
  Moderate = 4-5 symptoms     MODERATE   
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Appendix E 

































10. Depression/feeling blue 
 
 
11. Desire for sweets 
 
 
These phrases may or may not describe how you feel right now.  Please respond to 
each word or phrase with how you feel RIGHT NOW by drawing a vertical mark 
anywhere along the horizontal line. 
Not at all Extremely 
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Appendix F 
Questionnaire of Smoking Urges – Brief 
 
 




2. Nothing would be better than smoking 




3. If it were possible, I probably would 




4. I could control things better right now 
    if I could smoke. 
 
 














8. I would do almost anything for a 
    cigarette now. 
 
 









































   agree 
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   agree 
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Appendix G 



























7. Excessive salivation 
 
 
8. Heart pounding 
 
 






These phrases may or may not describe how you feel right now.  Please respond to 
each word or phrase with how you feel RIGHT NOW by drawing a vertical mark 
anywhere along the horizontal line. 
Not at all Extremely 
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Appendix H 











1. Was the product satisfying? 
 
 
2.  Was the product pleasant?  
 
 
3.  Did the product taste good?  
 
 
4.  Did the product make you dizzy? 
 
 
5.  Did the product calm you down? 
 
 
6.  Did the product help you concentrate? 
 
 
7.  Did the product make you feel more awake? 
 
 
8.  Did the product reduce your hunger for food? 
 
 










These phrases may or may not describe how you feel right now.  Please respond to 
each word or phrase with how you feel RIGHT NOW by drawing a vertical mark 
anywhere along the horizontal line. 
Not at all Extremely 
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Appendix I 
Multiple Choice Procedure 
 
Please choose between the two options. 
 
1. 10 puffs from your ECIG or $0.01 
2. 10 puffs from your ECIG or $0.02 
3. 10 puffs from your ECIG or $0.04 
4. 10 puffs from your ECIG or $0.08 
5. 10 puffs from your ECIG or $0.16 
6. 10 puffs from your ECIG or $0.32 
7. 10 puffs from your ECIG or $0.64 
8. 10 puffs from your ECIG or $1.28 
9. 10 puffs from your ECIG or $2.56 
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Appendix J 
ECIG Dependence Predictor Variables 
 
Table 5 demonstrates skew, kurtosis, and correlation with PSECDI scores for all 
variables. The outcome variable, PSECDI scores, was normally distributed though no predictor 
variables were normally distributed. For predictor variables, first, univariate outliers were 
truncated to the next lowest score for variables when z-scores > 3.2 and the reported value may 
not have been realistic (e.g. wattage of 157 for Juul, which is approximately 8 watts). One to 
three outliers were truncated for lifetime cigarettes, liquid/day, duration of use, and wattage. 
Though this improved the distribution of these variables, they were not normally distributed after 
handling of outliers.  
Lifetime cigarette use was highly skewed and kurtotic with a large standard error (Table 
X), so this variable was dichotomized into smoking status. Individuals that had used > 100 
cigarettes lifetime were classified as smokers (27.40%), and individuals that had used < 100 
lifetime cigarettes were considered nonsmokers (72.60%). Nonsmokers (M = 8.47, SEM = 0.40) 
and smokers (M = 8.58, SEM = 0.62) did not have significantly different PSEDCI scores, based 
on an independent-samples t-test [t(166) = -0.16, p = 0.88]. Nicotine concentration was retained 
for the model because a log transformation worsened skew and kurtosis for this variable (Table 
5). One concern for this variable was the low correlation with PSECDI scores. Log and square 
root transformation worsened skew and kurtosis for days/week (Table 5). Since 87.6% of 
respondents used ECIGs daily, days/week was dichotomized into daily and non-daily use for the 
final model. Daily ECIG users (M = 8.95, SEM = 0.36) had significantly higher PSEDCI scores 
than nondaily users (M = 5.52, SEM = 0.75), based on an independent samples t-test [t(168) = -
3.40, p = .001]. Log-transformed liquid/day was used in the model due to improved skew and 
kurtosis compared to the raw variable. One concern was the potential association between liquid 
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use/day and the PSEDCI question “How many times per day do you use your ECIG.” However, 
these variables were not significantly correlated (r = .07, p = 0.36), suggesting that liquid use/day 
could be retained in the model. Square root-transformed duration of use was used in the model 
due to acceptable skew and kurtosis after transformation. Log-transformed wattage was used in 
the model due to improved skew and kurtosis, though skew remained outside of the normal 
range. Log-transformed age was used to the model due to improved skew and kurtosis, despite 
being outside of the normal range (Table 5). 
Additionally, interactions between variables were explored. Specifically, nicotine x 
wattage, nicotine use/day (nicotine concentration x liquid use/day) and nicotine use/week 
(nicotine concentration x liquid use/day x days/week) were investigated.  Nicotine x wattage was 
of interest due to the high correlation between these variables (r = -.78, p < .001). However, 
these interaction variables had extreme levels of skew and kurtosis and were less normally 
distributed than the original variables. Additionally, these variables were not significantly 
correlated with dependence. Finally, the utility of these variables was unclear (e.g., how nicotine 
concentration and wattage interact to influence nicotine delivery is not well-characterized), so 
the original variables were determined to be more appropriate for the model. Juul use was 
considered as a variable rather than nicotine concentration and wattage because 60.74% of the 
sample used a Juul. Juul use was not significantly associated with PSECDI scores, t(168) = .04, p 
= 0.97, so the original variables were retained for the model.  
 
